Topoisomerase II alpha (TOP2A) is a member of a highly conserved group of enzymes that plays important roles in synthesis and transcription of DNA as well as chromosomal segregation during mitosis. The overexpression of TOP2A has been correlated with increased risk of progression in various cancers, and it has been a target for the development of anti-polymerase inhibitors to treat cancer.
T-Cell Immunoglobulin and Mucin-Domain-Containing Molecule-3 (TIM3) is present on T-helper type 1 lymphocytes and other immune cells, including dendritic cells and natural killer cells. TIM3 is overexpressed in CD4+ tumour-infiltrating lymphocytes, including those with non-small cell lung cancer associated with poor prognoses. TIM3 has recently emerged as a potential target for cancer immunotherapy.
T-Cell Immunoglobulin and Mucin-Domain-Containing Molecule-3 (TIM3) is present on T-helper type 1 lymphocytes and other immune cells, including dendritic cells and natural killer cells. TIM3 is overexpressed in CD4+ tumour-infiltrating lymphocytes, including those with non-small cell lung cancer associated with poor prognoses. TIM3 has recently emerged as a potential target for cancer immunotherapy.
T-Cell Immunoglobulin and Mucin-Domain-Containing Molecule-3 (TIM3) is present on T-helper type 1 lymphocytes and other immune cells, including dendritic cells and natural killer cells. TIM3 is overexpressed in CD4+ tumour-infiltrating lymphocytes, including those with non-small cell lung cancer associated with poor prognoses. TIM3 has recently emerged as a potential target for cancer immunotherapy.
T-Cell Immunoglobulin and Mucin-Domain-Containing Molecule-3 (TIM3) is present on T-helper type 1 lymphocytes and other immune cells, including dendritic cells and natural killer cells. TIM3 is overexpressed in CD4+ tumour-infiltrating lymphocytes, including those with non-small cell lung cancer associated with poor prognoses. TIM3 has recently emerged as a potential target for cancer immunotherapy.
TIGIT is an immune receptor present on some T cells and Natural Killer cells. TIGIT binds with high affinity to the poliovirus receptor (PVR) which causes increased secretion of IL10 and decreased secretion of IL12B and suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Through the CD226/TIGIT-PVR pathway, TIGIT regulates T cell mediated immunity. In cancer, TIGIT and PD-1 have been shown to be over-expressed on tumor antigen-specific CD8+ T cells and CD8+ tumor infiltrating lymphocytes (TILs) from individuals with melanoma. Blockade of TIGIT and PD-1 led to increased cell proliferation, cytokine production, and degranulation of tumor antigen-specific CD8+ T cells and TIL CD8+ T cells. It can be considered an immune checkpoint.
TIGIT is an immune receptor present on some T cells and Natural Killer cells. TIGIT binds with high affinity to the poliovirus receptor (PVR) which causes increased secretion of IL10 and decreased secretion of IL12B and suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Through the CD226/TIGIT-PVR pathway, TIGIT regulates T cell mediated immunity. In cancer, TIGIT and PD-1 have been shown to be over-expressed on tumor antigen-specific CD8+ T cells and CD8+ tumor infiltrating lymphocytes (TILs) from individuals with melanoma. Blockade of TIGIT and PD-1 led to increased cell proliferation, cytokine production, and degranulation of tumor antigen-specific CD8+ T cells and TIL CD8+ T cells. It can be considered an immune checkpoint.
TIGIT is an immune receptor present on some T cells and Natural Killer cells. TIGIT binds with high affinity to the poliovirus receptor (PVR) which causes increased secretion of IL10 and decreased secretion of IL12B and suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Through the CD226/TIGIT-PVR pathway, TIGIT regulates T cell mediated immunity. In cancer, TIGIT and PD-1 have been shown to be over-expressed on tumor antigen-specific CD8+ T cells and CD8+ tumor infiltrating lymphocytes (TILs) from individuals with melanoma. Blockade of TIGIT and PD-1 led to increased cell proliferation, cytokine production, and degranulation of tumor antigen-specific CD8+ T cells and TIL CD8+ T cells. It can be considered an immune checkpoint.
TIGIT is an immune receptor present on some T cells and Natural Killer cells. TIGIT binds with high affinity to the poliovirus receptor (PVR) which causes increased secretion of IL10 and decreased secretion of IL12B and suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Through the CD226/TIGIT-PVR pathway, TIGIT regulates T cell mediated immunity. In cancer, TIGIT and PD-1 have been shown to be over-expressed on tumor antigen-specific CD8+ T cells and CD8+ tumor infiltrating lymphocytes (TILs) from individuals with melanoma. Blockade of TIGIT and PD-1 led to increased cell proliferation, cytokine production, and degranulation of tumor antigen-specific CD8+ T cells and TIL CD8+ T cells. It can be considered an immune checkpoint.
Thyroglobulin is a precursor to the thyroid hormones T4 and T3, and is present in the thyroid follicular cells. Nearly all thyroid follicular carcinomas stain for thyroglobulin and sometimes produce a focal staining pattern. Conversely, poorly differentiated carcinomas and non-thyroid adenocarcinomas do not stain for thyroglobulin, therefore Anti-Thyroglobulin is a useful diagnostic tool for recognizing papillary and follicular thyroid carcinomas. A panel of Anti-Thyroglobulin and Anti-Calcitonin is useful for identifying medullary thyroid carcinomas, whereas a panel of Anti-Thyroglobulin and Anti-TTF1 is useful for distinguishing between primary thyroid and lung neoplasms.
Thyroglobulin is a precursor to the thyroid hormones T4 and T3, and is present in the thyroid follicular cells. Nearly all thyroid follicular carcinomas stain for thyroglobulin and sometimes produce a focal staining pattern. Conversely, poorly differentiated carcinomas and non-thyroid adenocarcinomas do not stain for thyroglobulin, therefore Anti-Thyroglobulin is a useful diagnostic tool for recognizing papillary and follicular thyroid carcinomas. A panel of Anti-Thyroglobulin and Anti-Calcitonin is useful for identifying medullary thyroid carcinomas, whereas a panel of Anti-Thyroglobulin and Anti-TTF1 is useful for distinguishing between primary thyroid and lung neoplasms.
Thyroglobulin is a precursor to the thyroid hormones T4 and T3, and is present in the thyroid follicular cells. Nearly all thyroid follicular carcinomas stain for thyroglobulin and sometimes produce a focal staining pattern. Conversely, poorly differentiated carcinomas and non-thyroid adenocarcinomas do not stain for thyroglobulin, therefore Anti-Thyroglobulin is a useful diagnostic tool for recognizing papillary and follicular thyroid carcinomas. A panel of Anti-Thyroglobulin and Anti-Calcitonin is useful for identifying medullary thyroid carcinomas, whereas a panel of Anti-Thyroglobulin and Anti-TTF1 is useful for distinguishing between primary thyroid and lung neoplasms.
Thyroglobulin is a precursor to the thyroid hormones T4 and T3, and is present in the thyroid follicular cells. Nearly all thyroid follicular carcinomas stain for thyroglobulin and sometimes produce a focal staining pattern. Conversely, poorly differentiated carcinomas and non-thyroid adenocarcinomas do not stain for thyroglobulin, therefore Anti-Thyroglobulin is a useful diagnostic tool for recognizing papillary and follicular thyroid carcinomas. A panel of Anti-Thyroglobulin and Anti-Calcitonin is useful for identifying medullary thyroid carcinomas, whereas a panel of Anti-Thyroglobulin and Anti-TTF1 is useful for distinguishing between primary thyroid and lung neoplasms.
Thymidylate Synthase (TS) is a crucial enzyme responsible for the synthesis of 2'-deoxythymidine-5'-monophosphate (dTMP) a precursor for thymidylate which is necessary for DNA replication and repair from 2'-deoxyuridine-5'-monophosphate (dUMP). In terms of cancer, TS is an important target for cancer treatment as the inhibition of TS and therefore nucleotide synthesis necessary for cell growth has shown to be a vital part for successful treatment against colorectal, pancreatic and breast cancers.
Product Type:
Positive Control Slides
Storage Temp:
-20 degrees Celsius
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Application Details:
1:200
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Thymidylate Synthase (TS) is a crucial enzyme responsible for the synthesis of 2'-deoxythymidine-5'-monophosphate (dTMP) a precursor for thymidylate which is necessary for DNA replication and repair from 2'-deoxyuridine-5'-monophosphate (dUMP). In terms of cancer, TS is an important target for cancer treatment as the inhibition of TS and therefore nucleotide synthesis necessary for cell growth has shown to be a vital part for successful treatment against colorectal, pancreatic and breast cancers.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC697
Antibody Isotype:
IgG1
Application Details:
1:200
Regulatory Status:
RUO
Positive Control:
Colon Cancer
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Thymidylate Synthase (TS) is a crucial enzyme responsible for the synthesis of 2'-deoxythymidine-5'-monophosphate (dTMP) a precursor for thymidylate which is necessary for DNA replication and repair from 2'-deoxyuridine-5'-monophosphate (dUMP). In terms of cancer, TS is an important target for cancer treatment as the inhibition of TS and therefore nucleotide synthesis necessary for cell growth has shown to be a vital part for successful treatment against colorectal, pancreatic and breast cancers.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC697
Antibody Isotype:
IgG1
Application Details:
1:200
Regulatory Status:
RUO
Positive Control:
Colon Cancer
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Thymidylate Synthase (TS) is a crucial enzyme responsible for the synthesis of 2'-deoxythymidine-5'-monophosphate (dTMP) a precursor for thymidylate which is necessary for DNA replication and repair from 2'-deoxyuridine-5'-monophosphate (dUMP). In terms of cancer, TS is an important target for cancer treatment as the inhibition of TS and therefore nucleotide synthesis necessary for cell growth has shown to be a vital part for successful treatment against colorectal, pancreatic and breast cancers.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Predilute
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC697
Antibody Isotype:
IgG1
Application Details:
1:200
Regulatory Status:
RUO
Positive Control:
Colon Cancer
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Transcription Factor E3 (TFE3) is a transcription factor that binds to the MUE3-type E-box sequences involved in TGF-β signaling. Anti-TFE3 staining is the most sensitive and specific indicator of Xp11 translocation renal cell carcinomas. Since alveolar soft part sarcoma (ASPS) is characterized by a specific chromosomal rearrangement resulting in a chimeric transcription factor (ASPSCR1-TFE3), this TFE3 IVD antibody is also a useful diagnostic tool for recognizing ASPS.
Transcription Factor E3 (TFE3) is a transcription factor that binds to the MUE3-type E-box sequences involved in TGF-β signaling. Anti-TFE3 staining is the most sensitive and specific indicator of Xp11 translocation renal cell carcinomas. Since alveolar soft part sarcoma (ASPS) is characterized by a specific chromosomal rearrangement resulting in a chimeric transcription factor (ASPSCR1-TFE3), this TFE3 IVD antibody is also a useful diagnostic tool for recognizing ASPS.
Transcription Factor E3 (TFE3) is a transcription factor that binds to the MUE3-type E-box sequences involved in TGF-β signaling. Anti-TFE3 staining is the most sensitive and specific indicator of Xp11 translocation renal cell carcinomas. Since alveolar soft part sarcoma (ASPS) is characterized by a specific chromosomal rearrangement resulting in a chimeric transcription factor (ASPSCR1-TFE3), this TFE3 IVD antibody is also a useful diagnostic tool for recognizing ASPS.
Transcription Factor E3 (TFE3) is a transcription factor that binds to the MUE3-type E-box sequences involved in TGF-β signaling. Anti-TFE3 staining is the most sensitive and specific indicator of Xp11 translocation renal cell carcinomas. Since alveolar soft part sarcoma (ASPS) is characterized by a specific chromosomal rearrangement resulting in a chimeric transcription factor (ASPSCR1-TFE3), this TFE3 IVD antibody is also a useful diagnostic tool for recognizing ASPS.
Terminal Deoxynucleotidyl Transferase (TdT) is a DNA polymerase present in normal and malignant pre-B- and pre-T-cells during early differentiation. Anti-TdT stains nearly all acute lymphoblastic lymphoma/leukemia (ALL) cases, but does not stain pre-B-cell ALL or mature B- and T-cells. Anti-TdT staining is also useful for identifying Type AB thymoma and some chronic myeloid leukemia.
Terminal Deoxynucleotidyl Transferase (TdT) is a DNA polymerase present in normal and malignant pre-B- and pre-T-cells during early differentiation. Anti-TdT stains nearly all acute lymphoblastic lymphoma/leukemia (ALL) cases, but does not stain pre-B-cell ALL or mature B- and T-cells. Anti-TdT staining is also useful for identifying Type AB thymoma and some chronic myeloid leukemia.
Terminal Deoxynucleotidyl Transferase (TdT) is a DNA polymerase present in normal and malignant pre-B- and pre-T-cells during early differentiation. Anti-TdT stains nearly all acute lymphoblastic lymphoma/leukemia (ALL) cases, but does not stain pre-B-cell ALL or mature B- and T-cells. Anti-TdT staining is also useful for identifying Type AB thymoma and some chronic myeloid leukemia.
Terminal Deoxynucleotidyl Transferase (TdT) is a DNA polymerase present in normal and malignant pre-B- and pre-T-cells during early differentiation. Anti-TdT stains nearly all acute lymphoblastic lymphoma/leukemia (ALL) cases, but does not stain pre-B-cell ALL or mature B- and T-cells. Anti-TdT staining is also useful for identifying Type AB thymoma and some chronic myeloid leukemia.
Tau proteins are abundant in neurons of the central nervous system, and function in microtubule stability and organization. Defects in Tau functioning and aggregation of these proteins have been clinically linked to a number of neurodegenerative disorders including Alzheimer’s disease, Parkinson’s disease, Pick’s disease (PiD), progressive supranuclear palsy (PSP), cortical basal degeneration (CBD), and frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17).
Tau proteins are abundant in neurons of the central nervous system, and function in microtubule stability and organization. Defects in Tau functioning and aggregation of these proteins have been clinically linked to a number of neurodegenerative disorders including Alzheimer’s disease, Parkinson’s disease, Pick’s disease (PiD), progressive supranuclear palsy (PSP), cortical basal degeneration (CBD), and frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17).
Tau proteins are abundant in neurons of the central nervous system, and function in microtubule stability and organization. Defects in Tau functioning and aggregation of these proteins have been clinically linked to a number of neurodegenerative disorders including Alzheimer’s disease, Parkinson’s disease, Pick’s disease (PiD), progressive supranuclear palsy (PSP), cortical basal degeneration (CBD), and frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17).
Tau proteins are abundant in neurons of the central nervous system, and function in microtubule stability and organization. Defects in Tau functioning and aggregation of these proteins have been clinically linked to a number of neurodegenerative disorders including Alzheimer’s disease, Parkinson’s disease, Pick’s disease (PiD), progressive supranuclear palsy (PSP), cortical basal degeneration (CBD), and frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17).
Tumour-Associated Glycoprotein 72 (TAG-72) is a glycoprotein found on the surface of many cancer pathologies. Anti-TAG-72 can be useful for detecting some adenocarcinomas and non-neoplastic tissues. This diagnostic grade TAG-72 IVD antibody is useful for identifying adenocarcinomas in positive staining, but in mesotheliomas no staining is observed.
Product Type:
Positive Control Slides
Storage Temp:
-20 degrees Celsius
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Application Details:
1:200
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Tumour-Associated Glycoprotein 72 (TAG-72) is a glycoprotein found on the surface of many cancer pathologies. Anti-TAG-72 can be useful for detecting some adenocarcinomas and non-neoplastic tissues. This diagnostic grade TAG-72 IVD antibody is useful for identifying adenocarcinomas in positive staining, but in mesotheliomas no staining is observed.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC072
Antibody Isotype:
IgG1, kappa
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Lung Adenocarcinoma
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Tumour-Associated Glycoprotein 72 (TAG-72) is a glycoprotein found on the surface of many cancer pathologies. Anti-TAG-72 can be useful for detecting some adenocarcinomas and non-neoplastic tissues. This diagnostic grade TAG-72 IVD antibody is useful for identifying adenocarcinomas in positive staining, but in mesotheliomas no staining is observed.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC072
Antibody Isotype:
IgG1, kappa
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Lung Adenocarcinoma
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Tumour-Associated Glycoprotein 72 (TAG-72) is a glycoprotein found on the surface of many cancer pathologies. Anti-TAG-72 can be useful for detecting some adenocarcinomas and non-neoplastic tissues. This diagnostic grade TAG-72 IVD antibody is useful for identifying adenocarcinomas in positive staining, but in mesotheliomas no staining is observed.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Predilute
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC072
Antibody Isotype:
IgG1, kappa
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Lung Adenocarcinoma
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Synaptophysin is a synaptic vesicle glycoprotein used in synaptic transmission of neurons. Anti-Synaptophysin stains the gastrointestinal mucosa and lung neuroendocrine cells of the human adrenal medulla, carotid body, pancreas, pituitary, skin, and thyroid. Synaptophysin also stains neuroendocrine neoplasms. Use of Anti-Synaptophysin produces diffuse, finely granular, cytoplasmic staining. The presence of synaptophysin does not correlate with neuron-specific enolase or other neuroendocrine markers.
Synaptophysin is a synaptic vesicle glycoprotein used in synaptic transmission of neurons. Anti-Synaptophysin stains the gastrointestinal mucosa and lung neuroendocrine cells of the human adrenal medulla, carotid body, pancreas, pituitary, skin, and thyroid. Synaptophysin also stains neuroendocrine neoplasms. Use of Anti-Synaptophysin produces diffuse, finely granular, cytoplasmic staining. The presence of synaptophysin does not correlate with neuron-specific enolase or other neuroendocrine markers.
Synaptophysin is a synaptic vesicle glycoprotein used in synaptic transmission of neurons. Anti-Synaptophysin stains the gastrointestinal mucosa and lung neuroendocrine cells of the human adrenal medulla, carotid body, pancreas, pituitary, skin, and thyroid. Synaptophysin also stains neuroendocrine neoplasms. Use of Anti-Synaptophysin produces diffuse, finely granular, cytoplasmic staining. The presence of synaptophysin does not correlate with neuron-specific enolase or other neuroendocrine markers.
Synaptophysin is a synaptic vesicle glycoprotein used in synaptic transmission of neurons. Anti-Synaptophysin stains the gastrointestinal mucosa and lung neuroendocrine cells of the human adrenal medulla, carotid body, pancreas, pituitary, skin, and thyroid. Synaptophysin also stains neuroendocrine neoplasms. Use of Anti-Synaptophysin produces diffuse, finely granular, cytoplasmic staining. The presence of synaptophysin does not correlate with neuron-specific enolase or other neuroendocrine markers.
Survivin is an apoptosis inhibitor that is nearly undetectable in terminally differentiated cells, but found in most tumours including renal cell carcinoma, ovarian carcinoma, hepatocellular carcinoma, prostate carcinoma, and breast carcinoma. Survivin expression is linked to tumour progression, but not patient survival.
Product Type:
Positive Control Slides
Storage Temp:
-20 degrees Celsius
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Application Details:
1:200
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Survivin is an apoptosis inhibitor that is nearly undetectable in terminally differentiated cells, but found in most tumours including renal cell carcinoma, ovarian carcinoma, hepatocellular carcinoma, prostate carcinoma, and breast carcinoma. Survivin expression is linked to tumour progression, but not patient survival.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC668
Antibody Isotype:
IgG1
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Lymphoma
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Survivin is an apoptosis inhibitor that is nearly undetectable in terminally differentiated cells, but found in most tumours including renal cell carcinoma, ovarian carcinoma, hepatocellular carcinoma, prostate carcinoma, and breast carcinoma. Survivin expression is linked to tumour progression, but not patient survival.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC668
Antibody Isotype:
IgG1
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Lymphoma
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Survivin is an apoptosis inhibitor that is nearly undetectable in terminally differentiated cells, but found in most tumours including renal cell carcinoma, ovarian carcinoma, hepatocellular carcinoma, prostate carcinoma, and breast carcinoma. Survivin expression is linked to tumour progression, but not patient survival.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Predilute
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC668
Antibody Isotype:
IgG1
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Lymphoma
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Stathmin regulates microtubule dynamics in the cell cycle. It is present in all tissues, but is mostly pronounced in constantly proliferating cell types. Anti-Stathmin staining has been found to correlate with cervical intraepithelial neoplasia (CIN) grade, with CIN 3 presenting the greatest expression and CIN 1 displaying the least expression of stathmin.
Stathmin regulates microtubule dynamics in the cell cycle. It is present in all tissues, but is mostly pronounced in constantly proliferating cell types. Anti-Stathmin staining has been found to correlate with cervical intraepithelial neoplasia (CIN) grade, with CIN 3 presenting the greatest expression and CIN 1 displaying the least expression of stathmin.
Stathmin regulates microtubule dynamics in the cell cycle. It is present in all tissues, but is mostly pronounced in constantly proliferating cell types. Anti-Stathmin staining has been found to correlate with cervical intraepithelial neoplasia (CIN) grade, with CIN 3 presenting the greatest expression and CIN 1 displaying the least expression of stathmin.
Stathmin regulates microtubule dynamics in the cell cycle. It is present in all tissues, but is mostly pronounced in constantly proliferating cell types. Anti-Stathmin staining has been found to correlate with cervical intraepithelial neoplasia (CIN) grade, with CIN 3 presenting the greatest expression and CIN 1 displaying the least expression of stathmin.
SPNS2 is a sphingolipid transporter expressed in the extraembryonic yolk syncytial layer (YSL). SPNS2 is required of migration of myocardial precursors, since it contributes in sphingosine 1-phosphate (S1P) secretion, which is a mediator that plays critical roles in cardiovascular, immunological, and neural development and function.
Product Type:
Positive Control Slides
Storage Temp:
-20 degrees Celsius
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Application Details:
1:200
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
SPNS2 is a sphingolipid transporter expressed in the extraembryonic yolk syncytial layer (YSL). SPNS2 is required of migration of myocardial precursors, since it contributes in sphingosine 1-phosphate (S1P) secretion, which is a mediator that plays critical roles in cardiovascular, immunological, and neural development and function.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC694
Antibody Isotype:
IgG1
Application Details:
1:200
Regulatory Status:
RUO
Positive Control:
Intestine
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
SPNS2 is a sphingolipid transporter expressed in the extraembryonic yolk syncytial layer (YSL). SPNS2 is required of migration of myocardial precursors, since it contributes in sphingosine 1-phosphate (S1P) secretion, which is a mediator that plays critical roles in cardiovascular, immunological, and neural development and function.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC694
Antibody Isotype:
IgG1
Application Details:
1:200
Regulatory Status:
RUO
Positive Control:
Intestine
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
SPNS2 is a sphingolipid transporter expressed in the extraembryonic yolk syncytial layer (YSL). SPNS2 is required of migration of myocardial precursors, since it contributes in sphingosine 1-phosphate (S1P) secretion, which is a mediator that plays critical roles in cardiovascular, immunological, and neural development and function.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Predilute
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC694
Antibody Isotype:
IgG1
Application Details:
1:200
Regulatory Status:
RUO
Positive Control:
Intestine
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
SOX-2, also known as SRY (Sex Determining Region Y)-Box 2, is a transcription factor that acts to regulate pluripotency of undifferentiated embryonic stem cells, and to regulate gene expression in the stomach. This diagnostic grade SOX-2 IVD antibody is used to detect melanoma, testicular germ cell tumour, cervical carcinoma, lung cancer, breast cancer with basal cell phenotype, and teratoma of the central nervous system. SOX-2 has been reported as a predictor of poor outcome in stage I lung adenocarcinomas. Anti-SOX-2 is also used to recognize squamous cell carcinomas of the lung and gastrointestinal tract, and may be useful for detecting embryonal carcinoma.
SOX-2, also known as SRY (Sex Determining Region Y)-Box 2, is a transcription factor that acts to regulate pluripotency of undifferentiated embryonic stem cells, and to regulate gene expression in the stomach. This diagnostic grade SOX-2 IVD antibody is used to detect melanoma, testicular germ cell tumour, cervical carcinoma, lung cancer, breast cancer with basal cell phenotype, and teratoma of the central nervous system. SOX-2 has been reported as a predictor of poor outcome in stage I lung adenocarcinomas. Anti-SOX-2 is also used to recognize squamous cell carcinomas of the lung and gastrointestinal tract, and may be useful for detecting embryonal carcinoma.
SOX-2, also known as SRY (Sex Determining Region Y)-Box 2, is a transcription factor that acts to regulate pluripotency of undifferentiated embryonic stem cells, and to regulate gene expression in the stomach. This diagnostic grade SOX-2 IVD antibody is used to detect melanoma, testicular germ cell tumour, cervical carcinoma, lung cancer, breast cancer with basal cell phenotype, and teratoma of the central nervous system. SOX-2 has been reported as a predictor of poor outcome in stage I lung adenocarcinomas. Anti-SOX-2 is also used to recognize squamous cell carcinomas of the lung and gastrointestinal tract, and may be useful for detecting embryonal carcinoma.
SOX-2, also known as SRY (Sex Determining Region Y)-Box 2, is a transcription factor that acts to regulate pluripotency of undifferentiated embryonic stem cells, and to regulate gene expression in the stomach. This diagnostic grade SOX-2 IVD antibody is used to detect melanoma, testicular germ cell tumour, cervical carcinoma, lung cancer, breast cancer with basal cell phenotype, and teratoma of the central nervous system. SOX-2 has been reported as a predictor of poor outcome in stage I lung adenocarcinomas. Anti-SOX-2 is also used to recognize squamous cell carcinomas of the lung and gastrointestinal tract, and may be useful for detecting embryonal carcinoma.
SRY (Sex Determining Region Y)-Box 11 (SOX11), also known as Transcription Factor SOX11, is a nuclear transcription factor that acts in regulation of embryonic development, cell differentiation, and the development of the human central nervous system. SOX11 is expressed in medulloblastoma and glioma, and has been indicated as a marker for both Cyclin D1-positive and -negative mantle cell lymphomas, Burkitt's lymphoma, and lymphoblastic lymphoma.
SRY (Sex Determining Region Y)-Box 11 (SOX11), also known as Transcription Factor SOX11, is a nuclear transcription factor that acts in regulation of embryonic development, cell differentiation, and the development of the human central nervous system. SOX11 is expressed in medulloblastoma and glioma, and has been indicated as a marker for both Cyclin D1-positive and -negative mantle cell lymphomas, Burkitt's lymphoma, and lymphoblastic lymphoma.
SRY (Sex Determining Region Y)-Box 11 (SOX11), also known as Transcription Factor SOX11, is a nuclear transcription factor that acts in regulation of embryonic development, cell differentiation, and the development of the human central nervous system. SOX11 is expressed in medulloblastoma and glioma, and has been indicated as a marker for both Cyclin D1-positive and -negative mantle cell lymphomas, Burkitt's lymphoma, and lymphoblastic lymphoma.
SRY (Sex Determining Region Y)-Box 11 (SOX11), also known as Transcription Factor SOX11, is a nuclear transcription factor that acts in regulation of embryonic development, cell differentiation, and the development of the human central nervous system. SOX11 is expressed in medulloblastoma and glioma, and has been indicated as a marker for both Cyclin D1-positive and -negative mantle cell lymphomas, Burkitt's lymphoma, and lymphoblastic lymphoma.
SRY (Sex Determining Region Y)-Box 10 (SOX-10), also known as Transcription Factor SOX-10, is a nuclear transcription factor that acts in regulation of embryonic development and in the specification and differentiation of cells of melanocytic lineage. SOX-10 is diffusely expressed in neurofibromas and schwannomas, and mutations in the SOX-10 gene are linked to Waardenburg-Shah and Waardenburg-Hirschsprung's disease. Anti-SOX-10 has been shown to be sensitive for conventional, spindled, and desmoplastic melanoma, and has been used to detect metastatic melanoma and nodal capsular nevus in sentinel lymph nodes.
SRY (Sex Determining Region Y)-Box 10 (SOX-10), also known as Transcription Factor SOX-10, is a nuclear transcription factor that acts in regulation of embryonic development and in the specification and differentiation of cells of melanocytic lineage. SOX-10 is diffusely expressed in neurofibromas and schwannomas, and mutations in the SOX-10 gene are linked to Waardenburg-Shah and Waardenburg-Hirschsprung's disease. Anti-SOX-10 has been shown to be sensitive for conventional, spindled, and desmoplastic melanoma, and has been used to detect metastatic melanoma and nodal capsular nevus in sentinel lymph nodes.
SRY (Sex Determining Region Y)-Box 10 (SOX-10), also known as Transcription Factor SOX-10, is a nuclear transcription factor that acts in regulation of embryonic development and in the specification and differentiation of cells of melanocytic lineage. SOX-10 is diffusely expressed in neurofibromas and schwannomas, and mutations in the SOX-10 gene are linked to Waardenburg-Shah and Waardenburg-Hirschsprung's disease. Anti-SOX-10 has been shown to be sensitive for conventional, spindled, and desmoplastic melanoma, and has been used to detect metastatic melanoma and nodal capsular nevus in sentinel lymph nodes.
SRY (Sex Determining Region Y)-Box 10 (SOX-10), also known as Transcription Factor SOX-10, is a nuclear transcription factor that acts in regulation of embryonic development and in the specification and differentiation of cells of melanocytic lineage. SOX-10 is diffusely expressed in neurofibromas and schwannomas, and mutations in the SOX-10 gene are linked to Waardenburg-Shah and Waardenburg-Hirschsprung's disease. Anti-SOX-10 has been shown to be sensitive for conventional, spindled, and desmoplastic melanoma, and has been used to detect metastatic melanoma and nodal capsular nevus in sentinel lymph nodes.
Sal-Like Protein 4 (SALL4) is a zinc finger transcription factor found in germ cells and human blood progenitor cells, with functional involvement in modulating Oct-4 to maintain embryonic stem cell pluripotency. SALL4 is a useful marker for acute myeloid leukemia, B-cell acute lymphocytic leukemia, intratubular germ cell neoplasia, seminomas/dysgerminomas, and yolk sac tumours (both pediatric and postpubertal). Anti-SALL4 is used to detect embryonal carcinomas, hepatocellular carcinoma (HCC), gliomas, ovarian primitive germ-cell tumours, choriocarcinomas, spermatogonia, teratoma, gastric cancer, breast cancer, and lung cancer. Expression of SALL4 is often associated with poor prognosis in HCC, and with metastasis in endometrial cancer, colorectal carcinoma, and esophageal squamous cell carcinoma.
Sal-Like Protein 4 (SALL4) is a zinc finger transcription factor found in germ cells and human blood progenitor cells, with functional involvement in modulating Oct-4 to maintain embryonic stem cell pluripotency. SALL4 is a useful marker for acute myeloid leukemia, B-cell acute lymphocytic leukemia, intratubular germ cell neoplasia, seminomas/dysgerminomas, and yolk sac tumours (both pediatric and postpubertal). Anti-SALL4 is used to detect embryonal carcinomas, hepatocellular carcinoma (HCC), gliomas, ovarian primitive germ-cell tumours, choriocarcinomas, spermatogonia, teratoma, gastric cancer, breast cancer, and lung cancer. Expression of SALL4 is often associated with poor prognosis in HCC, and with metastasis in endometrial cancer, colorectal carcinoma, and esophageal squamous cell carcinoma.
Sal-Like Protein 4 (SALL4) is a zinc finger transcription factor found in germ cells and human blood progenitor cells, with functional involvement in modulating Oct-4 to maintain embryonic stem cell pluripotency. SALL4 is a useful marker for acute myeloid leukemia, B-cell acute lymphocytic leukemia, intratubular germ cell neoplasia, seminomas/dysgerminomas, and yolk sac tumours (both pediatric and postpubertal). Anti-SALL4 is used to detect embryonal carcinomas, hepatocellular carcinoma (HCC), gliomas, ovarian primitive germ-cell tumours, choriocarcinomas, spermatogonia, teratoma, gastric cancer, breast cancer, and lung cancer. Expression of SALL4 is often associated with poor prognosis in HCC, and with metastasis in endometrial cancer, colorectal carcinoma, and esophageal squamous cell carcinoma.
Sal-Like Protein 4 (SALL4) is a zinc finger transcription factor found in germ cells and human blood progenitor cells, with functional involvement in modulating Oct-4 to maintain embryonic stem cell pluripotency. SALL4 is a useful marker for acute myeloid leukemia, B-cell acute lymphocytic leukemia, intratubular germ cell neoplasia, seminomas/dysgerminomas, and yolk sac tumours (both pediatric and postpubertal). Anti-SALL4 is used to detect embryonal carcinomas, hepatocellular carcinoma (HCC), gliomas, ovarian primitive germ-cell tumours, choriocarcinomas, spermatogonia, teratoma, gastric cancer, breast cancer, and lung cancer. Expression of SALL4 is often associated with poor prognosis in HCC, and with metastasis in endometrial cancer, colorectal carcinoma, and esophageal squamous cell carcinoma.
Serum Amyloid A1 (SAA1) is a member of the serum amyloid A family of apolipoproteins. Highly inducible SAA1 is an acute phase protein expressed in response to tissue injury and chronic inflammatory disease. The recent studies also suggest SAA1 is associated with tumor pathogenesis contributing to certain types of malignant tumors.
Serum Amyloid A1 (SAA1) is a member of the serum amyloid A family of apolipoproteins. Highly inducible SAA1 is an acute phase protein expressed in response to tissue injury and chronic inflammatory disease. The recent studies also suggest SAA1 is associated with tumor pathogenesis contributing to certain types of malignant tumors.
Serum Amyloid A1 (SAA1) is a member of the serum amyloid A family of apolipoproteins. Highly inducible SAA1 is an acute phase protein expressed in response to tissue injury and chronic inflammatory disease. The recent studies also suggest SAA1 is associated with tumor pathogenesis contributing to certain types of malignant tumors.
Serum Amyloid A1 (SAA1) is a member of the serum amyloid A family of apolipoproteins. Highly inducible SAA1 is an acute phase protein expressed in response to tissue injury and chronic inflammatory disease. The recent studies also suggest SAA1 is associated with tumor pathogenesis contributing to certain types of malignant tumors.
S-100 is a low-molecular weight protein found in Schwann cells, melanocytes, glial cells, histiocytes, lipocytes, skeletal and cardiac muscle, chondrocytes, adipocytes, myoepithelial cells, macrophages, Langerhans cells, dendritic cells, and keratinocytes. S-100 is a useful marker for Schwann cell-derived tumours and a number of well-differentiated tumours of the salivary gland, adipose and cartilaginous tissue. Anti-S-100 is used to detect melanomas, histiocytosis X, malignant peripheral nerve sheath tumours, and clear cell sarcomas.
S-100 is a low-molecular weight protein found in Schwann cells, melanocytes, glial cells, histiocytes, lipocytes, skeletal and cardiac muscle, chondrocytes, adipocytes, myoepithelial cells, macrophages, Langerhans cells, dendritic cells, and keratinocytes. S-100 is a useful marker for Schwann cell-derived tumours and a number of well-differentiated tumours of the salivary gland, adipose and cartilaginous tissue. Anti-S-100 is used to detect melanomas, histiocytosis X, malignant peripheral nerve sheath tumours, and clear cell sarcomas.
S-100 is a low-molecular weight protein found in Schwann cells, melanocytes, glial cells, histiocytes, lipocytes, skeletal and cardiac muscle, chondrocytes, adipocytes, myoepithelial cells, macrophages, Langerhans cells, dendritic cells, and keratinocytes. S-100 is a useful marker for Schwann cell-derived tumours and a number of well-differentiated tumours of the salivary gland, adipose and cartilaginous tissue. Anti-S-100 is used to detect melanomas, histiocytosis X, malignant peripheral nerve sheath tumours, and clear cell sarcomas.
S-100 is a low-molecular weight protein found in Schwann cells, melanocytes, glial cells, histiocytes, lipocytes, skeletal and cardiac muscle, chondrocytes, adipocytes, myoepithelial cells, macrophages, Langerhans cells, dendritic cells, and keratinocytes. S-100 is a useful marker for Schwann cell-derived tumours and a number of well-differentiated tumours of the salivary gland, adipose and cartilaginous tissue. Anti-S-100 is used to detect melanomas, histiocytosis X, malignant peripheral nerve sheath tumours, and clear cell sarcomas.
ROS1 serves as a receptor tyrosine kinase. Gene rearrangement events involving ROS1 have been described in lung and other cancers, and such tumors have been found to be remarkably responsive to small molecule tyrosine kinase inhibitors. Multiple studies have demonstrated an incidence of approximately 1% in lung cancers, demonstrated oncogenicity, and showed that inhibition of tumor cells bearing ROS1 gene fusions by crizotinib or other ROS1 tyrosine kinase inhibitors was effective in vitro.
ROS1 serves as a receptor tyrosine kinase. Gene rearrangement events involving ROS1 have been described in lung and other cancers, and such tumors have been found to be remarkably responsive to small molecule tyrosine kinase inhibitors. Multiple studies have demonstrated an incidence of approximately 1% in lung cancers, demonstrated oncogenicity, and showed that inhibition of tumor cells bearing ROS1 gene fusions by crizotinib or other ROS1 tyrosine kinase inhibitors was effective in vitro.
ROS1 serves as a receptor tyrosine kinase. Gene rearrangement events involving ROS1 have been described in lung and other cancers, and such tumors have been found to be remarkably responsive to small molecule tyrosine kinase inhibitors. Multiple studies have demonstrated an incidence of approximately 1% in lung cancers, demonstrated oncogenicity, and showed that inhibition of tumor cells bearing ROS1 gene fusions by crizotinib or other ROS1 tyrosine kinase inhibitors was effective in vitro.
ROS1 serves as a receptor tyrosine kinase. Gene rearrangement events involving ROS1 have been described in lung and other cancers, and such tumors have been found to be remarkably responsive to small molecule tyrosine kinase inhibitors. Multiple studies have demonstrated an incidence of approximately 1% in lung cancers, demonstrated oncogenicity, and showed that inhibition of tumor cells bearing ROS1 gene fusions by crizotinib or other ROS1 tyrosine kinase inhibitors was effective in vitro.
Prostatic Specific Acid Phosphatase (PSAP) is a prostatic enzyme found in the glandular epithelium of the prostate. PSAP levels are elevated in hyperplastic prostate and prostate carcinoma, with the highest levels being detected in metastasized prostate cancer. Moderate overexpression of PSAP is also characteristic of diseases of the bone (such as Paget's disease or hyperparathyroidism), diseases of blood cells (such as sickle-cell disease), multiple myeloma, or lysosomal storage diseases (such as Gaucher's disease). PSAP is considered more sensitive, yet less specific, than PSA, however Anti-PSAP can act as a useful complement to Anti-PSA under suitable clinical contexts.
Product Type:
Positive Control Slides
Storage Temp:
-20 degrees Celsius
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Application Details:
1:200
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Prostatic Specific Acid Phosphatase (PSAP) is a prostatic enzyme found in the glandular epithelium of the prostate. PSAP levels are elevated in hyperplastic prostate and prostate carcinoma, with the highest levels being detected in metastasized prostate cancer. Moderate overexpression of PSAP is also characteristic of diseases of the bone (such as Paget's disease or hyperparathyroidism), diseases of blood cells (such as sickle-cell disease), multiple myeloma, or lysosomal storage diseases (such as Gaucher's disease). PSAP is considered more sensitive, yet less specific, than PSA, however Anti-PSAP can act as a useful complement to Anti-PSA under suitable clinical contexts.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC655
Antibody Isotype:
IgG1
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Prostate, Prostate Adenocarcinoma
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Prostatic Specific Acid Phosphatase (PSAP) is a prostatic enzyme found in the glandular epithelium of the prostate. PSAP levels are elevated in hyperplastic prostate and prostate carcinoma, with the highest levels being detected in metastasized prostate cancer. Moderate overexpression of PSAP is also characteristic of diseases of the bone (such as Paget's disease or hyperparathyroidism), diseases of blood cells (such as sickle-cell disease), multiple myeloma, or lysosomal storage diseases (such as Gaucher's disease). PSAP is considered more sensitive, yet less specific, than PSA, however Anti-PSAP can act as a useful complement to Anti-PSA under suitable clinical contexts.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC655
Antibody Isotype:
IgG1
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Prostate, Prostate Adenocarcinoma
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Prostatic Specific Acid Phosphatase (PSAP) is a prostatic enzyme found in the glandular epithelium of the prostate. PSAP levels are elevated in hyperplastic prostate and prostate carcinoma, with the highest levels being detected in metastasized prostate cancer. Moderate overexpression of PSAP is also characteristic of diseases of the bone (such as Paget's disease or hyperparathyroidism), diseases of blood cells (such as sickle-cell disease), multiple myeloma, or lysosomal storage diseases (such as Gaucher's disease). PSAP is considered more sensitive, yet less specific, than PSA, however Anti-PSAP can act as a useful complement to Anti-PSA under suitable clinical contexts.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Predilute
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC655
Antibody Isotype:
IgG1
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Prostate, Prostate Adenocarcinoma
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Prostate-Specific Antigen (PSA) is a serine protease of the kallikrein family that is produced by the prostate epithelium and epithelial lining of the periurethral glands. Although considered prostate-specific, PSA has also been detected in breast tissue, breast tumours, endometrium, adrenal neoplasms, and renal cell carcinomas. Anti-PSA can be used for differentiating high-grade prostate adenocarcinoma from high-grade urothelial carcinoma, as well as for determining the prostatic origin of carcinomas in non-prostate tissues. Anti-PSA recognizes primary and metastatic prostatic neoplasms, but not tumours of nonprostatic origin, and can be useful as an aid to confirm prostatic acinar cell origin in primary and metastatic carcinomas.
Prostate-Specific Antigen (PSA) is a serine protease of the kallikrein family that is produced by the prostate epithelium and epithelial lining of the periurethral glands. Although considered prostate-specific, PSA has also been detected in breast tissue, breast tumours, endometrium, adrenal neoplasms, and renal cell carcinomas. Anti-PSA can be used for differentiating high-grade prostate adenocarcinoma from high-grade urothelial carcinoma, as well as for determining the prostatic origin of carcinomas in non-prostate tissues. Anti-PSA recognizes primary and metastatic prostatic neoplasms, but not tumours of nonprostatic origin, and can be useful as an aid to confirm prostatic acinar cell origin in primary and metastatic carcinomas.
Prostate-Specific Antigen (PSA) is a serine protease of the kallikrein family that is produced by the prostate epithelium and epithelial lining of the periurethral glands. Although considered prostate-specific, PSA has also been detected in breast tissue, breast tumours, endometrium, adrenal neoplasms, and renal cell carcinomas. Anti-PSA can be used for differentiating high-grade prostate adenocarcinoma from high-grade urothelial carcinoma, as well as for determining the prostatic origin of carcinomas in non-prostate tissues. Anti-PSA recognizes primary and metastatic prostatic neoplasms, but not tumours of nonprostatic origin, and can be useful as an aid to confirm prostatic acinar cell origin in primary and metastatic carcinomas.
Prostate-Specific Antigen (PSA) is a serine protease of the kallikrein family that is produced by the prostate epithelium and epithelial lining of the periurethral glands. Although considered prostate-specific, PSA has also been detected in breast tissue, breast tumours, endometrium, adrenal neoplasms, and renal cell carcinomas. Anti-PSA can be used for differentiating high-grade prostate adenocarcinoma from high-grade urothelial carcinoma, as well as for determining the prostatic origin of carcinomas in non-prostate tissues. Anti-PSA recognizes primary and metastatic prostatic neoplasms, but not tumours of nonprostatic origin, and can be useful as an aid to confirm prostatic acinar cell origin in primary and metastatic carcinomas.
Prolactin (PRL) is a peptide hormone synthesized and secreted by lactotroph cells in the adenohypophysis (anterior pituitary gland). PRL plays a role in a number of processes including cell growth, reproduction, and immune function, with its primary function being associated with lactation. Anti-Prolactin reacts with lactotroph cells, and is useful in classification of pituitary tumours and the study of pituitary disease.
Product Type:
Positive Control Slides
Storage Temp:
-20 degrees Celsius
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Application Details:
1:200
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Prolactin (PRL) is a peptide hormone synthesized and secreted by lactotroph cells in the adenohypophysis (anterior pituitary gland). PRL plays a role in a number of processes including cell growth, reproduction, and immune function, with its primary function being associated with lactation. Anti-Prolactin reacts with lactotroph cells, and is useful in classification of pituitary tumours and the study of pituitary disease.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC652
Antibody Isotype:
IgG2
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Pituitary
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Prolactin (PRL) is a peptide hormone synthesized and secreted by lactotroph cells in the adenohypophysis (anterior pituitary gland). PRL plays a role in a number of processes including cell growth, reproduction, and immune function, with its primary function being associated with lactation. Anti-Prolactin reacts with lactotroph cells, and is useful in classification of pituitary tumours and the study of pituitary disease.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC652
Antibody Isotype:
IgG2
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Pituitary
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Prolactin (PRL) is a peptide hormone synthesized and secreted by lactotroph cells in the adenohypophysis (anterior pituitary gland). PRL plays a role in a number of processes including cell growth, reproduction, and immune function, with its primary function being associated with lactation. Anti-Prolactin reacts with lactotroph cells, and is useful in classification of pituitary tumours and the study of pituitary disease.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Predilute
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC652
Antibody Isotype:
IgG2
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Pituitary
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Progesterone Receptor (PR), also known as NR3C3 (Nuclear Receptor Subfamily 3, Group C, Member 3), is an intracellular steroid receptor which mediates the physiological effects of progesterone, a female sex hormone involved in the menstrual cycle, pregnancy, and embryogenesis. Progesterone receptor expression has been linked to the prediction of prognosis in breast cancer, as well as associated responses to endocrine therapy. The progesterone receptor has also been linked to risk for ovarian cancer.
Progesterone Receptor (PR), also known as NR3C3 (Nuclear Receptor Subfamily 3, Group C, Member 3), is an intracellular steroid receptor which mediates the physiological effects of progesterone, a female sex hormone involved in the menstrual cycle, pregnancy, and embryogenesis. Progesterone receptor expression has been linked to the prediction of prognosis in breast cancer, as well as associated responses to endocrine therapy. The progesterone receptor has also been linked to risk for ovarian cancer.
Progesterone Receptor (PR), also known as NR3C3 (Nuclear Receptor Subfamily 3, Group C, Member 3), is an intracellular steroid receptor which mediates the physiological effects of progesterone, a female sex hormone involved in the menstrual cycle, pregnancy, and embryogenesis. Progesterone receptor expression has been linked to the prediction of prognosis in breast cancer, as well as associated responses to endocrine therapy. The progesterone receptor has also been linked to risk for ovarian cancer.
Progesterone Receptor (PR), also known as NR3C3 (Nuclear Receptor Subfamily 3, Group C, Member 3), is an intracellular steroid receptor which mediates the physiological effects of progesterone, a female sex hormone involved in the menstrual cycle, pregnancy, and embryogenesis. Progesterone receptor expression has been linked to the prediction of prognosis in breast cancer, as well as associated responses to endocrine therapy. The progesterone receptor has also been linked to risk for ovarian cancer.
Progesterone Receptor (PR), also known as NR3C3 (Nuclear Receptor Subfamily 3, Group C, Member 3), is an intracellular steroid receptor which mediates the physiological effects of progesterone, a female sex hormone involved in the menstrual cycle, pregnancy, and embryogenesis. Progesterone receptor expression has been linked to the prediction of prognosis in breast cancer, as well as associated responses to endocrine therapy. The progesterone receptor has also been linked to risk for ovarian cancer.
Progesterone Receptor (PR), also known as NR3C3 (Nuclear Receptor Subfamily 3, Group C, Member 3), is an intracellular steroid receptor which mediates the physiological effects of progesterone, a female sex hormone involved in the menstrual cycle, pregnancy, and embryogenesis. Progesterone receptor expression has been linked to the prediction of prognosis in breast cancer, as well as associated responses to endocrine therapy. The progesterone receptor has also been linked to risk for ovarian cancer.
Progesterone Receptor (PR), also known as NR3C3 (Nuclear Receptor Subfamily 3, Group C, Member 3), is an intracellular steroid receptor which mediates the physiological effects of progesterone, a female sex hormone involved in the menstrual cycle, pregnancy, and embryogenesis. Progesterone receptor expression has been linked to the prediction of prognosis in breast cancer, as well as associated responses to endocrine therapy. The progesterone receptor has also been linked to risk for ovarian cancer.
Progesterone Receptor (PR), also known as NR3C3 (Nuclear Receptor Subfamily 3, Group C, Member 3), is an intracellular steroid receptor which mediates the physiological effects of progesterone, a female sex hormone involved in the menstrual cycle, pregnancy, and embryogenesis. Progesterone receptor expression has been linked to the prediction of prognosis in breast cancer, as well as associated responses to endocrine therapy. The progesterone receptor has also been linked to risk for ovarian cancer.
Procalcitonin (PCT) belongs to a group of related proteins including calcitonin gene-related peptides I and II, amylin, adrenomodulin and calcitonin (CAPA peptide family). Under normal metabolic conditions, PCT is only present in the C cells of the thyroid gland. In bacterial infection and sepsis, however, intact PCT is found in the blood and, more importantly, its level is related to the severity of bacterial sepsis. Today, PCT is considered to be one of the earliest and most specific markers of sepsis.
Product Type:
Positive Control Slides
Storage Temp:
-20 degrees Celsius
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Application Details:
1:200
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Procalcitonin (PCT) belongs to a group of related proteins including calcitonin gene-related peptides I and II, amylin, adrenomodulin and calcitonin (CAPA peptide family). Under normal metabolic conditions, PCT is only present in the C cells of the thyroid gland. In bacterial infection and sepsis, however, intact PCT is found in the blood and, more importantly, its level is related to the severity of bacterial sepsis. Today, PCT is considered to be one of the earliest and most specific markers of sepsis.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC699
Antibody Isotype:
IgG1
Application Details:
1:200
Regulatory Status:
RUO
Positive Control:
Thyroid
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Procalcitonin (PCT) belongs to a group of related proteins including calcitonin gene-related peptides I and II, amylin, adrenomodulin and calcitonin (CAPA peptide family). Under normal metabolic conditions, PCT is only present in the C cells of the thyroid gland. In bacterial infection and sepsis, however, intact PCT is found in the blood and, more importantly, its level is related to the severity of bacterial sepsis. Today, PCT is considered to be one of the earliest and most specific markers of sepsis.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC699
Antibody Isotype:
IgG1
Application Details:
1:200
Regulatory Status:
RUO
Positive Control:
Thyroid
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Procalcitonin (PCT) belongs to a group of related proteins including calcitonin gene-related peptides I and II, amylin, adrenomodulin and calcitonin (CAPA peptide family). Under normal metabolic conditions, PCT is only present in the C cells of the thyroid gland. In bacterial infection and sepsis, however, intact PCT is found in the blood and, more importantly, its level is related to the severity of bacterial sepsis. Today, PCT is considered to be one of the earliest and most specific markers of sepsis.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Predilute
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC699
Antibody Isotype:
IgG1
Application Details:
1:200
Regulatory Status:
RUO
Positive Control:
Thyroid
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Podoplanin is a transmembrane mucoprotein specifically expressed in the endothelium of lymphatic capillaries, while remaining absent from the blood vasculature. The protein is co-localized with VEGFR3/FLT4 in normal skin and kidney. Anti-Podoplanin is useful in the identification of lymphangiomas, Kaposi's sarcomas, epithelioid mesotheliomas, hemangioblastomas, seminomas, and some angiosarcomas that likely have lymphatic differentiation.
Podoplanin is a transmembrane mucoprotein specifically expressed in the endothelium of lymphatic capillaries, while remaining absent from the blood vasculature. The protein is co-localized with VEGFR3/FLT4 in normal skin and kidney. Anti-Podoplanin is useful in the identification of lymphangiomas, Kaposi's sarcomas, epithelioid mesotheliomas, hemangioblastomas, seminomas, and some angiosarcomas that likely have lymphatic differentiation.
Podoplanin is a transmembrane mucoprotein specifically expressed in the endothelium of lymphatic capillaries, while remaining absent from the blood vasculature. The protein is co-localized with VEGFR3/FLT4 in normal skin and kidney. Anti-Podoplanin is useful in the identification of lymphangiomas, Kaposi's sarcomas, epithelioid mesotheliomas, hemangioblastomas, seminomas, and some angiosarcomas that likely have lymphatic differentiation.
Podoplanin is a transmembrane mucoprotein specifically expressed in the endothelium of lymphatic capillaries, while remaining absent from the blood vasculature. The protein is co-localized with VEGFR3/FLT4 in normal skin and kidney. Anti-Podoplanin is useful in the identification of lymphangiomas, Kaposi's sarcomas, epithelioid mesotheliomas, hemangioblastomas, seminomas, and some angiosarcomas that likely have lymphatic differentiation.
Postmeiotic Segregation Increased 2 (PMS2) is a DNA repair protein involved in mismatch repair. Mutations and deficiencies in the PMS2 gene have been linked to microsatellite instability and malignancies such as hereditary nonpolyposis colorectal cancer and endometrial cancer. Expression levels of the PMS2 protein may be useful as a screening tool for Lynch syndrome after a colorectal cancer diagnosis. Anti-PMS2 is recommended to be used as part of a panel along with antibodies against MSH2, MSH6, and MLH1.
Postmeiotic Segregation Increased 2 (PMS2) is a DNA repair protein involved in mismatch repair. Mutations and deficiencies in the PMS2 gene have been linked to microsatellite instability and malignancies such as hereditary nonpolyposis colorectal cancer and endometrial cancer. Expression levels of the PMS2 protein may be useful as a screening tool for Lynch syndrome after a colorectal cancer diagnosis. Anti-PMS2 is recommended to be used as part of a panel along with antibodies against MSH2, MSH6, and MLH1.
Postmeiotic Segregation Increased 2 (PMS2) is a DNA repair protein involved in mismatch repair. Mutations and deficiencies in the PMS2 gene have been linked to microsatellite instability and malignancies such as hereditary nonpolyposis colorectal cancer and endometrial cancer. Expression levels of the PMS2 protein may be useful as a screening tool for Lynch syndrome after a colorectal cancer diagnosis. Anti-PMS2 is recommended to be used as part of a panel along with antibodies against MSH2, MSH6, and MLH1.
Postmeiotic Segregation Increased 2 (PMS2) is a DNA repair protein involved in mismatch repair. Mutations and deficiencies in the PMS2 gene have been linked to microsatellite instability and malignancies such as hereditary nonpolyposis colorectal cancer and endometrial cancer. Expression levels of the PMS2 protein may be useful as a screening tool for Lynch syndrome after a colorectal cancer diagnosis. Anti-PMS2 is recommended to be used as part of a panel along with antibodies against MSH2, MSH6, and MLH1.
Postmeiotic Segregation Increased 2 (PMS2) is a DNA repair protein involved in mismatch repair. Mutations and deficiencies in the PMS2 gene have been linked to microsatellite instability and malignancies such as hereditary nonpolyposis colorectal cancer and endometrial cancer. Expression levels of the PMS2 protein may be useful as a screening tool for Lynch syndrome after a colorectal cancer diagnosis. Anti-PMS2 is recommended to be used as part of a panel along with antibodies against MSH2, MSH6, and MLH1.
Postmeiotic Segregation Increased 2 (PMS2) is a DNA repair protein involved in mismatch repair. Mutations and deficiencies in the PMS2 gene have been linked to microsatellite instability and malignancies such as hereditary nonpolyposis colorectal cancer and endometrial cancer. Expression levels of the PMS2 protein may be useful as a screening tool for Lynch syndrome after a colorectal cancer diagnosis. Anti-PMS2 is recommended to be used as part of a panel along with antibodies against MSH2, MSH6, and MLH1.
Postmeiotic Segregation Increased 2 (PMS2) is a DNA repair protein involved in mismatch repair. Mutations and deficiencies in the PMS2 gene have been linked to microsatellite instability and malignancies such as hereditary nonpolyposis colorectal cancer and endometrial cancer. Expression levels of the PMS2 protein may be useful as a screening tool for Lynch syndrome after a colorectal cancer diagnosis. Anti-PMS2 is recommended to be used as part of a panel along with antibodies against MSH2, MSH6, and MLH1.
Postmeiotic Segregation Increased 2 (PMS2) is a DNA repair protein involved in mismatch repair. Mutations and deficiencies in the PMS2 gene have been linked to microsatellite instability and malignancies such as hereditary nonpolyposis colorectal cancer and endometrial cancer. Expression levels of the PMS2 protein may be useful as a screening tool for Lynch syndrome after a colorectal cancer diagnosis. Anti-PMS2 is recommended to be used as part of a panel along with antibodies against MSH2, MSH6, and MLH1.
Perforin, a pore-forming protein found in the granules of cytotoxic T-lymphocytes and natural killer cells, functions to enable granzymes to enter the target cells and activate apoptosis. Perforin expression is upregulated in activated CD8+ T-cells, and these cells have been identified to have a major influence in Th1-associated inflammatory skin diseases. It has been suggested that perforin plays a role in alloimmunity, being involved in both the cytolytic process of rejection as well as downregulation of the T-cell mediated responses associated with the alloimmune response. Perforin-mediated cytotoxicity has also been linked to a number of autoimmune diseases.
Product Type:
Positive Control Slides
Storage Temp:
-20 degrees Celsius
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Application Details:
1:200
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Perforin, a pore-forming protein found in the granules of cytotoxic T-lymphocytes and natural killer cells, functions to enable granzymes to enter the target cells and activate apoptosis. Perforin expression is upregulated in activated CD8+ T-cells, and these cells have been identified to have a major influence in Th1-associated inflammatory skin diseases. It has been suggested that perforin plays a role in alloimmunity, being involved in both the cytolytic process of rejection as well as downregulation of the T-cell mediated responses associated with the alloimmune response. Perforin-mediated cytotoxicity has also been linked to a number of autoimmune diseases.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC646
Antibody Isotype:
IgG1
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Spleen
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Perforin, a pore-forming protein found in the granules of cytotoxic T-lymphocytes and natural killer cells, functions to enable granzymes to enter the target cells and activate apoptosis. Perforin expression is upregulated in activated CD8+ T-cells, and these cells have been identified to have a major influence in Th1-associated inflammatory skin diseases. It has been suggested that perforin plays a role in alloimmunity, being involved in both the cytolytic process of rejection as well as downregulation of the T-cell mediated responses associated with the alloimmune response. Perforin-mediated cytotoxicity has also been linked to a number of autoimmune diseases.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC646
Antibody Isotype:
IgG1
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Spleen
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Perforin, a pore-forming protein found in the granules of cytotoxic T-lymphocytes and natural killer cells, functions to enable granzymes to enter the target cells and activate apoptosis. Perforin expression is upregulated in activated CD8+ T-cells, and these cells have been identified to have a major influence in Th1-associated inflammatory skin diseases. It has been suggested that perforin plays a role in alloimmunity, being involved in both the cytolytic process of rejection as well as downregulation of the T-cell mediated responses associated with the alloimmune response. Perforin-mediated cytotoxicity has also been linked to a number of autoimmune diseases.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Predilute
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC646
Antibody Isotype:
IgG1
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Spleen
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Programmed Death-Ligand 1 (PD-L1), CD274, or B7 Homolog 1 (B7-H1), is a transmembrane protein involved in suppressing the immune system and rendering tumour cells resistant to lysis through binding of the Programmed Death-1 (PD-1) receptor. Overexpression of PD-L1 may allow cancer cells to evade the actions of the host immune system. In renal cell carcinoma, upregulation of PD-L1 has been linked to increased tumour aggressiveness and risk of death. When considered in adjunct with CD8+ tumour-infiltrating lymphocyte density, expression levels of PD-L1 may be a useful predictor of multiple cancer types, including stage III non-small-cell lung cancer, hormone receptor negative breast cancer, and sentinel lymph node melanoma.
Programmed Death-Ligand 1 (PD-L1), CD274, or B7 Homolog 1 (B7-H1), is a transmembrane protein involved in suppressing the immune system and rendering tumour cells resistant to lysis through binding of the Programmed Death-1 (PD-1) receptor. Overexpression of PD-L1 may allow cancer cells to evade the actions of the host immune system. In renal cell carcinoma, upregulation of PD-L1 has been linked to increased tumour aggressiveness and risk of death. When considered in adjunct with CD8+ tumour-infiltrating lymphocyte density, expression levels of PD-L1 may be a useful predictor of multiple cancer types, including stage III non-small-cell lung cancer, hormone receptor negative breast cancer, and sentinel lymph node melanoma.
Programmed Death-Ligand 1 (PD-L1), CD274, or B7 Homolog 1 (B7-H1), is a transmembrane protein involved in suppressing the immune system and rendering tumour cells resistant to lysis through binding of the Programmed Death-1 (PD-1) receptor. Overexpression of PD-L1 may allow cancer cells to evade the actions of the host immune system. In renal cell carcinoma, upregulation of PD-L1 has been linked to increased tumour aggressiveness and risk of death. When considered in adjunct with CD8+ tumour-infiltrating lymphocyte density, expression levels of PD-L1 may be a useful predictor of multiple cancer types, including stage III non-small-cell lung cancer, hormone receptor negative breast cancer, and sentinel lymph node melanoma.
Programmed Death-Ligand 1 (PD-L1), CD274, or B7 Homolog 1 (B7-H1), is a transmembrane protein involved in suppressing the immune system and rendering tumour cells resistant to lysis through binding of the Programmed Death-1 (PD-1) receptor. Overexpression of PD-L1 may allow cancer cells to evade the actions of the host immune system. In renal cell carcinoma, upregulation of PD-L1 has been linked to increased tumour aggressiveness and risk of death. When considered in adjunct with CD8+ tumour-infiltrating lymphocyte density, expression levels of PD-L1 may be a useful predictor of multiple cancer types, including stage III non-small-cell lung cancer, hormone receptor negative breast cancer, and sentinel lymph node melanoma.
Programmed Death-Ligand 1 (PD-L1), CD274, or B7 Homolog 1 (B7-H1), is a transmembrane protein involved in suppressing the immune system and rendering tumour cells resistant to lysis through binding of the Programmed Death-1 (PD-1) receptor. Overexpression of PD-L1 may allow cancer cells to evade the actions of the host immune system. In renal cell carcinoma, upregulation of PD-L1 has been linked to increased tumour aggressiveness and risk of death. When considered in adjunct with CD8+ tumour-infiltrating lymphocyte density, expression levels of PD-L1 may be a useful predictor of multiple cancer types, including stage III non-small-cell lung cancer, hormone receptor negative breast cancer, and sentinel lymph node melanoma.
Programmed Death-Ligand 1 (PD-L1), CD274, or B7 Homolog 1 (B7-H1), is a transmembrane protein involved in suppressing the immune system and rendering tumour cells resistant to lysis through binding of the Programmed Death-1 (PD-1) receptor. Overexpression of PD-L1 may allow cancer cells to evade the actions of the host immune system. In renal cell carcinoma, upregulation of PD-L1 has been linked to increased tumour aggressiveness and risk of death. When considered in adjunct with CD8+ tumour-infiltrating lymphocyte density, expression levels of PD-L1 may be a useful predictor of multiple cancer types, including stage III non-small-cell lung cancer, hormone receptor negative breast cancer, and sentinel lymph node melanoma.
Programmed Death-Ligand 1 (PD-L1), CD274, or B7 Homolog 1 (B7-H1), is a transmembrane protein involved in suppressing the immune system and rendering tumour cells resistant to lysis through binding of the Programmed Death-1 (PD-1) receptor. Overexpression of PD-L1 may allow cancer cells to evade the actions of the host immune system. In renal cell carcinoma, upregulation of PD-L1 has been linked to increased tumour aggressiveness and risk of death. When considered in adjunct with CD8+ tumour-infiltrating lymphocyte density, expression levels of PD-L1 may be a useful predictor of multiple cancer types, including stage III non-small-cell lung cancer, hormone receptor negative breast cancer, and sentinel lymph node melanoma.
Programmed Death-Ligand 1 (PD-L1), CD274, or B7 Homolog 1 (B7-H1), is a transmembrane protein involved in suppressing the immune system and rendering tumour cells resistant to lysis through binding of the Programmed Death-1 (PD-1) receptor. Overexpression of PD-L1 may allow cancer cells to evade the actions of the host immune system. In renal cell carcinoma, upregulation of PD-L1 has been linked to increased tumour aggressiveness and risk of death. When considered in adjunct with CD8+ tumour-infiltrating lymphocyte density, expression levels of PD-L1 may be a useful predictor of multiple cancer types, including stage III non-small-cell lung cancer, hormone receptor negative breast cancer, and sentinel lymph node melanoma.
Programmed Death 1 (PD-1) is a member of the CD28/CTLA-4 family of T-cell regulators, expressed as a co-receptor on the surface of activated T-cells, B-cells, and macrophages. New studies have suggested that the PD-1/PD-L1 signaling pathway may be linked to anti-tumour immunity, as PD-L1 has been shown to induce apoptosis of activated T-cells or inhibit activity of cytotoxic T-cells. In comparison to CD10 and Bcl-6, PD-1 is expressed by fewer B-cells and has therefore been considered a more specific and useful diagnostic marker for angioimmunoblastic T-cell lymphoma. Therapies targeted toward the PD-1 receptor have shown remarkable clinical responses in patients with various types of cancer, including non-small-cell lung cancer, melanoma, and renal-cell cancer.
Programmed Death 1 (PD-1) is a member of the CD28/CTLA-4 family of T-cell regulators, expressed as a co-receptor on the surface of activated T-cells, B-cells, and macrophages. New studies have suggested that the PD-1/PD-L1 signaling pathway may be linked to anti-tumour immunity, as PD-L1 has been shown to induce apoptosis of activated T-cells or inhibit activity of cytotoxic T-cells. In comparison to CD10 and Bcl-6, PD-1 is expressed by fewer B-cells and has therefore been considered a more specific and useful diagnostic marker for angioimmunoblastic T-cell lymphoma. Therapies targeted toward the PD-1 receptor have shown remarkable clinical responses in patients with various types of cancer, including non-small-cell lung cancer, melanoma, and renal-cell cancer.
Programmed Death 1 (PD-1) is a member of the CD28/CTLA-4 family of T-cell regulators, expressed as a co-receptor on the surface of activated T-cells, B-cells, and macrophages. New studies have suggested that the PD-1/PD-L1 signaling pathway may be linked to anti-tumour immunity, as PD-L1 has been shown to induce apoptosis of activated T-cells or inhibit activity of cytotoxic T-cells. In comparison to CD10 and Bcl-6, PD-1 is expressed by fewer B-cells and has therefore been considered a more specific and useful diagnostic marker for angioimmunoblastic T-cell lymphoma. Therapies targeted toward the PD-1 receptor have shown remarkable clinical responses in patients with various types of cancer, including non-small-cell lung cancer, melanoma, and renal-cell cancer.
Programmed Death 1 (PD-1) is a member of the CD28/CTLA-4 family of T-cell regulators, expressed as a co-receptor on the surface of activated T-cells, B-cells, and macrophages. New studies have suggested that the PD-1/PD-L1 signaling pathway may be linked to anti-tumour immunity, as PD-L1 has been shown to induce apoptosis of activated T-cells or inhibit activity of cytotoxic T-cells. In comparison to CD10 and Bcl-6, PD-1 is expressed by fewer B-cells and has therefore been considered a more specific and useful diagnostic marker for angioimmunoblastic T-cell lymphoma. Therapies targeted toward the PD-1 receptor have shown remarkable clinical responses in patients with various types of cancer, including non-small-cell lung cancer, melanoma, and renal-cell cancer.
PAX8 is expressed in simple ovarian inclusion cysts and non-ciliated mucosal cells of the fallopian tubes, but is absent from normal ovarian surface epithelial cells. Mutations in the PAX8 gene are linked to thyroid follicular carcinomas, atypical thyroid adenomas, and thyroid dysgenesis. Reports have associated PAX8 expression with renal carcinoma, nephroblastoma, and seminoma, and have indicated PAX8 as a useful marker for renal epithelial tumours, ovarian cancer, and for differential diagnoses in lung and neck tumours. Anti-PAX8 can be useful in determining the primary site of invasive micropapillary carcinomas of ovary from bladder, lung, and breast, when used in adjunct with a panel of organ-specific markers such as uroplakin, mammaglobin, and TTF-1.
PAX8 is expressed in simple ovarian inclusion cysts and non-ciliated mucosal cells of the fallopian tubes, but is absent from normal ovarian surface epithelial cells. Mutations in the PAX8 gene are linked to thyroid follicular carcinomas, atypical thyroid adenomas, and thyroid dysgenesis. Reports have associated PAX8 expression with renal carcinoma, nephroblastoma, and seminoma, and have indicated PAX8 as a useful marker for renal epithelial tumours, ovarian cancer, and for differential diagnoses in lung and neck tumours. Anti-PAX8 can be useful in determining the primary site of invasive micropapillary carcinomas of ovary from bladder, lung, and breast, when used in adjunct with a panel of organ-specific markers such as uroplakin, mammaglobin, and TTF-1.
PAX8 is expressed in simple ovarian inclusion cysts and non-ciliated mucosal cells of the fallopian tubes, but is absent from normal ovarian surface epithelial cells. Mutations in the PAX8 gene are linked to thyroid follicular carcinomas, atypical thyroid adenomas, and thyroid dysgenesis. Reports have associated PAX8 expression with renal carcinoma, nephroblastoma, and seminoma, and have indicated PAX8 as a useful marker for renal epithelial tumours, ovarian cancer, and for differential diagnoses in lung and neck tumours. Anti-PAX8 can be useful in determining the primary site of invasive micropapillary carcinomas of ovary from bladder, lung, and breast, when used in adjunct with a panel of organ-specific markers such as uroplakin, mammaglobin, and TTF-1.
PAX8 is expressed in simple ovarian inclusion cysts and non-ciliated mucosal cells of the fallopian tubes, but is absent from normal ovarian surface epithelial cells. Mutations in the PAX8 gene are linked to thyroid follicular carcinomas, atypical thyroid adenomas, and thyroid dysgenesis. Reports have associated PAX8 expression with renal carcinoma, nephroblastoma, and seminoma, and have indicated PAX8 as a useful marker for renal epithelial tumours, ovarian cancer, and for differential diagnoses in lung and neck tumours. Anti-PAX8 can be useful in determining the primary site of invasive micropapillary carcinomas of ovary from bladder, lung, and breast, when used in adjunct with a panel of organ-specific markers such as uroplakin, mammaglobin, and TTF-1.
PAX8 is expressed in simple ovarian inclusion cysts and non-ciliated mucosal cells of the fallopian tubes, but is absent from normal ovarian surface epithelial cells. Mutations in the PAX8 gene are linked to thyroid follicular carcinomas, atypical thyroid adenomas, and thyroid dysgenesis. Reports have associated PAX8 expression with renal carcinoma, nephroblastoma, and seminoma, and have indicated PAX8 as a useful marker for renal epithelial tumours, ovarian cancer, and for differential diagnoses in lung and neck tumours. Anti-PAX8 can be useful in determining the primary site of invasive micropapillary carcinomas of ovary from bladder, lung, and breast, when used in adjunct with a panel of organ-specific markers such as uroplakin, mammaglobin, and TTF-1.
PAX8 is expressed in simple ovarian inclusion cysts and non-ciliated mucosal cells of the fallopian tubes, but is absent from normal ovarian surface epithelial cells. Mutations in the PAX8 gene are linked to thyroid follicular carcinomas, atypical thyroid adenomas, and thyroid dysgenesis. Reports have associated PAX8 expression with renal carcinoma, nephroblastoma, and seminoma, and have indicated PAX8 as a useful marker for renal epithelial tumours, ovarian cancer, and for differential diagnoses in lung and neck tumours. Anti-PAX8 can be useful in determining the primary site of invasive micropapillary carcinomas of ovary from bladder, lung, and breast, when used in adjunct with a panel of organ-specific markers such as uroplakin, mammaglobin, and TTF-1.
PAX8 is expressed in simple ovarian inclusion cysts and non-ciliated mucosal cells of the fallopian tubes, but is absent from normal ovarian surface epithelial cells. Mutations in the PAX8 gene are linked to thyroid follicular carcinomas, atypical thyroid adenomas, and thyroid dysgenesis. Reports have associated PAX8 expression with renal carcinoma, nephroblastoma, and seminoma, and have indicated PAX8 as a useful marker for renal epithelial tumours, ovarian cancer, and for differential diagnoses in lung and neck tumours. Anti-PAX8 can be useful in determining the primary site of invasive micropapillary carcinomas of ovary from bladder, lung, and breast, when used in adjunct with a panel of organ-specific markers such as uroplakin, mammaglobin, and TTF-1.
PAX8 is expressed in simple ovarian inclusion cysts and non-ciliated mucosal cells of the fallopian tubes, but is absent from normal ovarian surface epithelial cells. Mutations in the PAX8 gene are linked to thyroid follicular carcinomas, atypical thyroid adenomas, and thyroid dysgenesis. Reports have associated PAX8 expression with renal carcinoma, nephroblastoma, and seminoma, and have indicated PAX8 as a useful marker for renal epithelial tumours, ovarian cancer, and for differential diagnoses in lung and neck tumours. Anti-PAX8 can be useful in determining the primary site of invasive micropapillary carcinomas of ovary from bladder, lung, and breast, when used in adjunct with a panel of organ-specific markers such as uroplakin, mammaglobin, and TTF-1.
PAX5 is a member of the paired box (PAX) family of transcription factors, which are key regulators in early development. The PAX5 gene encodes the B-cell lineage specific activator protein (BSAP), whose expression is limited to early stages of B-cell differentiation. Anti-PAX5 is useful in differentiating between classic Hodgkin's lymphoma versus multiple myeloma and solitary plasmacytoma, as the protein is expressed in mature and precursor B-cell non-Hodgkin's lymphomas/leukemias while being absent from the other two conditions. Diffuse large B-cell lymphomas are positive for PAX5, with the exception of those with terminal B-cell differentiation, and T-cell neoplasms do not stain with Anti-PAX5.
PAX5 is a member of the paired box (PAX) family of transcription factors, which are key regulators in early development. The PAX5 gene encodes the B-cell lineage specific activator protein (BSAP), whose expression is limited to early stages of B-cell differentiation. Anti-PAX5 is useful in differentiating between classic Hodgkin's lymphoma versus multiple myeloma and solitary plasmacytoma, as the protein is expressed in mature and precursor B-cell non-Hodgkin's lymphomas/leukemias while being absent from the other two conditions. Diffuse large B-cell lymphomas are positive for PAX5, with the exception of those with terminal B-cell differentiation, and T-cell neoplasms do not stain with Anti-PAX5.
PAX5 is a member of the paired box (PAX) family of transcription factors, which are key regulators in early development. The PAX5 gene encodes the B-cell lineage specific activator protein (BSAP), whose expression is limited to early stages of B-cell differentiation. Anti-PAX5 is useful in differentiating between classic Hodgkin's lymphoma versus multiple myeloma and solitary plasmacytoma, as the protein is expressed in mature and precursor B-cell non-Hodgkin's lymphomas/leukemias while being absent from the other two conditions. Diffuse large B-cell lymphomas are positive for PAX5, with the exception of those with terminal B-cell differentiation, and T-cell neoplasms do not stain with Anti-PAX5.
PAX5 is a member of the paired box (PAX) family of transcription factors, which are key regulators in early development. The PAX5 gene encodes the B-cell lineage specific activator protein (BSAP), whose expression is limited to early stages of B-cell differentiation. Anti-PAX5 is useful in differentiating between classic Hodgkin's lymphoma versus multiple myeloma and solitary plasmacytoma, as the protein is expressed in mature and precursor B-cell non-Hodgkin's lymphomas/leukemias while being absent from the other two conditions. Diffuse large B-cell lymphomas are positive for PAX5, with the exception of those with terminal B-cell differentiation, and T-cell neoplasms do not stain with Anti-PAX5.
PAX-2 is a homeogene that is expressed during kidney developing. Its expression was observed within the metanephric mesenchyma and plays a key role in mesenchyma-epithelium conversion. PAX-2 has been demonstrated to be expressed in renal carcinoma cell lines and has a potential role in the proliferation of these cell lines. Anti-PAX-2 antibodies may be useful in differentiating ovarian serous papilary carcinomas from breast carcinomas.
Product Type:
Positive Control Slides
Storage Temp:
-20 degrees Celsius
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Application Details:
1:200
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
PAX-2 is a homeogene that is expressed during kidney developing. Its expression was observed within the metanephric mesenchyma and plays a key role in mesenchyma-epithelium conversion. PAX-2 has been demonstrated to be expressed in renal carcinoma cell lines and has a potential role in the proliferation of these cell lines. Anti-PAX-2 antibodies may be useful in differentiating ovarian serous papilary carcinomas from breast carcinomas.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Rabbit
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC052
Antibody Isotype:
IgG
Application Details:
1:200
Regulatory Status:
RUO
Positive Control:
Renal Cell Carcinoma
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
PAX-2 is a homeogene that is expressed during kidney developing. Its expression was observed within the metanephric mesenchyma and plays a key role in mesenchyma-epithelium conversion. PAX-2 has been demonstrated to be expressed in renal carcinoma cell lines and has a potential role in the proliferation of these cell lines. Anti-PAX-2 antibodies may be useful in differentiating ovarian serous papilary carcinomas from breast carcinomas.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Rabbit
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC052
Antibody Isotype:
IgG
Application Details:
1:200
Regulatory Status:
RUO
Positive Control:
Renal Cell Carcinoma
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
PAX-2 is a homeogene that is expressed during kidney developing. Its expression was observed within the metanephric mesenchyma and plays a key role in mesenchyma-epithelium conversion. PAX-2 has been demonstrated to be expressed in renal carcinoma cell lines and has a potential role in the proliferation of these cell lines. Anti-PAX-2 antibodies may be useful in differentiating ovarian serous papilary carcinomas from breast carcinomas.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Predilute
Storage Temp:
-20 degrees Celsius
Host Animal:
Rabbit
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC052
Antibody Isotype:
IgG
Application Details:
1:200
Regulatory Status:
RUO
Positive Control:
Renal Cell Carcinoma
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Parathyroid Hormone (PTH), also known as Parathormone or Parathyrin, is a hormone secreted by the parathyroid glands that functions to increase the concentration of calcium in the blood. Anti-Parathyroid Hormone (PTH) is useful for differentiating parathyroid hyperplasia/neoplasms from thyroid and metastatic neoplasms, and is also used in the consideration of parathyroid carcinomas located primarily in the anterior mediastinum.
Parathyroid Hormone (PTH), also known as Parathormone or Parathyrin, is a hormone secreted by the parathyroid glands that functions to increase the concentration of calcium in the blood. Anti-Parathyroid Hormone (PTH) is useful for differentiating parathyroid hyperplasia/neoplasms from thyroid and metastatic neoplasms, and is also used in the consideration of parathyroid carcinomas located primarily in the anterior mediastinum.
Parathyroid Hormone (PTH), also known as Parathormone or Parathyrin, is a hormone secreted by the parathyroid glands that functions to increase the concentration of calcium in the blood. Anti-Parathyroid Hormone (PTH) is useful for differentiating parathyroid hyperplasia/neoplasms from thyroid and metastatic neoplasms, and is also used in the consideration of parathyroid carcinomas located primarily in the anterior mediastinum.
Parathyroid Hormone (PTH), also known as Parathormone or Parathyrin, is a hormone secreted by the parathyroid glands that functions to increase the concentration of calcium in the blood. Anti-Parathyroid Hormone (PTH) is useful for differentiating parathyroid hyperplasia/neoplasms from thyroid and metastatic neoplasms, and is also used in the consideration of parathyroid carcinomas located primarily in the anterior mediastinum.
p63 is a tumour suppressor protein that is very similar to p53 in structure and function, while being homologous to p73. p63 is important in development and differentiation, and has been identified as a useful marker for distinguishing between lung squamous cell carcinomas and adenocarcinomas. Anti-p63 is also used to differentiate between benign and malignant prostate and breast lesions, due to its labeling of the nuclei of myoepithelial cells in both tissue types.
p63 is a tumour suppressor protein that is very similar to p53 in structure and function, while being homologous to p73. p63 is important in development and differentiation, and has been identified as a useful marker for distinguishing between lung squamous cell carcinomas and adenocarcinomas. Anti-p63 is also used to differentiate between benign and malignant prostate and breast lesions, due to its labeling of the nuclei of myoepithelial cells in both tissue types.
p63 is a tumour suppressor protein that is very similar to p53 in structure and function, while being homologous to p73. p63 is important in development and differentiation, and has been identified as a useful marker for distinguishing between lung squamous cell carcinomas and adenocarcinomas. Anti-p63 is also used to differentiate between benign and malignant prostate and breast lesions, due to its labeling of the nuclei of myoepithelial cells in both tissue types.
p63 is a tumour suppressor protein that is very similar to p53 in structure and function, while being homologous to p73. p63 is important in development and differentiation, and has been identified as a useful marker for distinguishing between lung squamous cell carcinomas and adenocarcinomas. Anti-p63 is also used to differentiate between benign and malignant prostate and breast lesions, due to its labeling of the nuclei of myoepithelial cells in both tissue types.
p57<sup>Kip2</sup>, also known as p57, is a tumour suppressor protein that causes cell cycle arrest at G1 by binding to G1 cyclin-CDK complexes. The p57<sup>Kip2</sup> gene is a potential tumour suppressor target as the gene is located in a chromosomal region implicated in sporadic cancers, Wilms' tumour, and Beckwith Wiedemann syndrome. Anti-p57<sup>Kip2</sup> labels many cytotrophoblast nuclei and stromal cells in normal placenta, and is useful in differentiating between complete hydatidiform mole and partial hydatidiform mole or hydropic abortion.
p57<sup>Kip2</sup>, also known as p57, is a tumour suppressor protein that causes cell cycle arrest at G1 by binding to G1 cyclin-CDK complexes. The p57<sup>Kip2</sup> gene is a potential tumour suppressor target as the gene is located in a chromosomal region implicated in sporadic cancers, Wilms' tumour, and Beckwith Wiedemann syndrome. Anti-p57<sup>Kip2</sup> labels many cytotrophoblast nuclei and stromal cells in normal placenta, and is useful in differentiating between complete hydatidiform mole and partial hydatidiform mole or hydropic abortion.
p57<sup>Kip2</sup>, also known as p57, is a tumour suppressor protein that causes cell cycle arrest at G1 by binding to G1 cyclin-CDK complexes. The p57<sup>Kip2</sup> gene is a potential tumour suppressor target as the gene is located in a chromosomal region implicated in sporadic cancers, Wilms' tumour, and Beckwith Wiedemann syndrome. Anti-p57<sup>Kip2</sup> labels many cytotrophoblast nuclei and stromal cells in normal placenta, and is useful in differentiating between complete hydatidiform mole and partial hydatidiform mole or hydropic abortion.
p57<sup>Kip2</sup>, also known as p57, is a tumour suppressor protein that causes cell cycle arrest at G1 by binding to G1 cyclin-CDK complexes. The p57<sup>Kip2</sup> gene is a potential tumour suppressor target as the gene is located in a chromosomal region implicated in sporadic cancers, Wilms' tumour, and Beckwith Wiedemann syndrome. Anti-p57<sup>Kip2</sup> labels many cytotrophoblast nuclei and stromal cells in normal placenta, and is useful in differentiating between complete hydatidiform mole and partial hydatidiform mole or hydropic abortion.
p53, also known as Tumour Protein 53 or TP53, is a tumour suppressor and transcription factor that functions in a number of anti-cancer activities including DNA repair, cell-cycle arrest, and apoptosis in response to DNA damage or other stressors. Mutations in p53 are linked to a number of malignant tumours, including those of the breast, ovary, bladder, colon, lung, and melanoma. Anti-p53 staining has been used to detect intratubular germ cell neoplasia, and also to distinguish between uterine serous carcinoma and endometrioid carcinoma.
p53, also known as Tumour Protein 53 or TP53, is a tumour suppressor and transcription factor that functions in a number of anti-cancer activities including DNA repair, cell-cycle arrest, and apoptosis in response to DNA damage or other stressors. Mutations in p53 are linked to a number of malignant tumours, including those of the breast, ovary, bladder, colon, lung, and melanoma. Anti-p53 staining has been used to detect intratubular germ cell neoplasia, and also to distinguish between uterine serous carcinoma and endometrioid carcinoma.
p53, also known as Tumour Protein 53 or TP53, is a tumour suppressor and transcription factor that functions in a number of anti-cancer activities including DNA repair, cell-cycle arrest, and apoptosis in response to DNA damage or other stressors. Mutations in p53 are linked to a number of malignant tumours, including those of the breast, ovary, bladder, colon, lung, and melanoma. Anti-p53 staining has been used to detect intratubular germ cell neoplasia, and also to distinguish between uterine serous carcinoma and endometrioid carcinoma.
p53, also known as Tumour Protein 53 or TP53, is a tumour suppressor and transcription factor that functions in a number of anti-cancer activities including DNA repair, cell-cycle arrest, and apoptosis in response to DNA damage or other stressors. Mutations in p53 are linked to a number of malignant tumours, including those of the breast, ovary, bladder, colon, lung, and melanoma. Anti-p53 staining has been used to detect intratubular germ cell neoplasia, and also to distinguish between uterine serous carcinoma and endometrioid carcinoma.
p504s, also known as ?-Methylacyl Coenzyme A Racemase (AMACR), is an enzyme localized in the peroxisome and mitochondria that functions in ?-oxidation of branched chain fatty acids, as well as bile synthesis. AMACR has been clinically indicated as a tissue biomarker for prostate cancer and colorectal cancer, as well as high-grade prostatic intraepithelial neoplasia, a precursor lesion of prostate cancer. p504s overexpression has also been detected in a number of other cancers including ovarian, breast, bladder, lung, and renal cell carcinomas, lymphoma, and melanoma.
p504s, also known as ?-Methylacyl Coenzyme A Racemase (AMACR), is an enzyme localized in the peroxisome and mitochondria that functions in ?-oxidation of branched chain fatty acids, as well as bile synthesis. AMACR has been clinically indicated as a tissue biomarker for prostate cancer and colorectal cancer, as well as high-grade prostatic intraepithelial neoplasia, a precursor lesion of prostate cancer. p504s overexpression has also been detected in a number of other cancers including ovarian, breast, bladder, lung, and renal cell carcinomas, lymphoma, and melanoma.
p504s, also known as ?-Methylacyl Coenzyme A Racemase (AMACR), is an enzyme localized in the peroxisome and mitochondria that functions in ?-oxidation of branched chain fatty acids, as well as bile synthesis. AMACR has been clinically indicated as a tissue biomarker for prostate cancer and colorectal cancer, as well as high-grade prostatic intraepithelial neoplasia, a precursor lesion of prostate cancer. p504s overexpression has also been detected in a number of other cancers including ovarian, breast, bladder, lung, and renal cell carcinomas, lymphoma, and melanoma.
p504s, also known as ?-Methylacyl Coenzyme A Racemase (AMACR), is an enzyme localized in the peroxisome and mitochondria that functions in ?-oxidation of branched chain fatty acids, as well as bile synthesis. AMACR has been clinically indicated as a tissue biomarker for prostate cancer and colorectal cancer, as well as high-grade prostatic intraepithelial neoplasia, a precursor lesion of prostate cancer. p504s overexpression has also been detected in a number of other cancers including ovarian, breast, bladder, lung, and renal cell carcinomas, lymphoma, and melanoma.
Anti-p40 recognizes squamous and basal cells, the shortest variant of p53, and ΔNp63 (an isoform of p63). p40 has been indicated as an alternative to p63 for the detection of Squamous Cell Carcinoma (SqCC), offering the advantage of eliminating potential misinterpretation of a positive adenocarcinoma as a SqCC.
Anti-p40 recognizes squamous and basal cells, the shortest variant of p53, and ΔNp63 (an isoform of p63). p40 has been indicated as an alternative to p63 for the detection of Squamous Cell Carcinoma (SqCC), offering the advantage of eliminating potential misinterpretation of a positive adenocarcinoma as a SqCC.
Anti-p40 recognizes squamous and basal cells, the shortest variant of p53, and ΔNp63 (an isoform of p63). p40 has been indicated as an alternative to p63 for the detection of Squamous Cell Carcinoma (SqCC), offering the advantage of eliminating potential misinterpretation of a positive adenocarcinoma as a SqCC.
Anti-p40 recognizes squamous and basal cells, the shortest variant of p53, and ΔNp63 (an isoform of p63). p40 has been indicated as an alternative to p63 for the detection of Squamous Cell Carcinoma (SqCC), offering the advantage of eliminating potential misinterpretation of a positive adenocarcinoma as a SqCC.
Anti-p40 recognizes squamous and basal cells, the shortest variant of p53, and ΔNp63 (an isoform of p63). p40 has been indicated as an alternative to p63 for the detection of Squamous Cell Carcinoma (SqCC), offering the advantage of eliminating potential misinterpretation of a positive adenocarcinoma as a SqCC.
Anti-p40 recognizes squamous and basal cells, the shortest variant of p53, and ΔNp63 (an isoform of p63). p40 has been indicated as an alternative to p63 for the detection of Squamous Cell Carcinoma (SqCC), offering the advantage of eliminating potential misinterpretation of a positive adenocarcinoma as a SqCC.
Anti-p40 recognizes squamous and basal cells, the shortest variant of p53, and ΔNp63 (an isoform of p63). p40 has been indicated as an alternative to p63 for the detection of Squamous Cell Carcinoma (SqCC), offering the advantage of eliminating potential misinterpretation of a positive adenocarcinoma as a SqCC.
Anti-p40 recognizes squamous and basal cells, the shortest variant of p53, and ΔNp63 (an isoform of p63). p40 has been indicated as an alternative to p63 for the detection of Squamous Cell Carcinoma (SqCC), offering the advantage of eliminating potential misinterpretation of a positive adenocarcinoma as a SqCC.
p27, also known as p27<sup>Kip1</sup>, is a cyclin-dependent kinase inhibitor that binds to and inhibits cyclin-dependent kinases, thereby regulating progression from G1 to S phase. Decreased expression of p27 is linked to poor prognosis in renal-cell carcinoma, colon carcinoma, small breast carcinomas, non-small-cell lung carcinoma, hepatocellular carcinoma, multiple myeloma, lymph node metastases in papillary carcinoma of the thyroid, and is associated with a more aggressive phenotype of carcinoma in the cervix.
Product Type:
Positive Control Slides
Storage Temp:
-20 degrees Celsius
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Application Details:
1:200
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
p27, also known as p27<sup>Kip1</sup>, is a cyclin-dependent kinase inhibitor that binds to and inhibits cyclin-dependent kinases, thereby regulating progression from G1 to S phase. Decreased expression of p27 is linked to poor prognosis in renal-cell carcinoma, colon carcinoma, small breast carcinomas, non-small-cell lung carcinoma, hepatocellular carcinoma, multiple myeloma, lymph node metastases in papillary carcinoma of the thyroid, and is associated with a more aggressive phenotype of carcinoma in the cervix.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC027
Antibody Isotype:
IgG1, kappa
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Tonsil
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
p27, also known as p27<sup>Kip1</sup>, is a cyclin-dependent kinase inhibitor that binds to and inhibits cyclin-dependent kinases, thereby regulating progression from G1 to S phase. Decreased expression of p27 is linked to poor prognosis in renal-cell carcinoma, colon carcinoma, small breast carcinomas, non-small-cell lung carcinoma, hepatocellular carcinoma, multiple myeloma, lymph node metastases in papillary carcinoma of the thyroid, and is associated with a more aggressive phenotype of carcinoma in the cervix.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC027
Antibody Isotype:
IgG1, kappa
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Tonsil
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
p27, also known as p27<sup>Kip1</sup>, is a cyclin-dependent kinase inhibitor that binds to and inhibits cyclin-dependent kinases, thereby regulating progression from G1 to S phase. Decreased expression of p27 is linked to poor prognosis in renal-cell carcinoma, colon carcinoma, small breast carcinomas, non-small-cell lung carcinoma, hepatocellular carcinoma, multiple myeloma, lymph node metastases in papillary carcinoma of the thyroid, and is associated with a more aggressive phenotype of carcinoma in the cervix.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Predilute
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC027
Antibody Isotype:
IgG1, kappa
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Tonsil
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
The p16 (p16<sup>INK4A</sup>) protein is a cyclin-dependent kinase (CDK) inhibitor that plays an important regulatory role in the cell cycle. By controlling the transition between the G1 and S phases through regulation of retinoblastoma protein, p16 decelerates cellular differentiation and therefore acts as a tumor suppressor, making it the key marker in several human cancers including head and neck cancer, perianal lesions, melanomas, gliomas, lymphomas, and some types of leukemia. p16 is also clinically indicated in carcinomas of the esophagus, pancreas, lung, biliary tract, liver, colon, and urinary bladder.
The p16 (p16<sup>INK4A</sup>) protein is a cyclin-dependent kinase (CDK) inhibitor that plays an important regulatory role in the cell cycle. By controlling the transition between the G1 and S phases through regulation of retinoblastoma protein, p16 decelerates cellular differentiation and therefore acts as a tumor suppressor, making it the key marker in several human cancers including head and neck cancer, perianal lesions, melanomas, gliomas, lymphomas, and some types of leukemia. p16 is also clinically indicated in carcinomas of the esophagus, pancreas, lung, biliary tract, liver, colon, and urinary bladder.
The p16 (p16<sup>INK4A</sup>) protein is a cyclin-dependent kinase (CDK) inhibitor that plays an important regulatory role in the cell cycle. By controlling the transition between the G1 and S phases through regulation of retinoblastoma protein, p16 decelerates cellular differentiation and therefore acts as a tumor suppressor, making it the key marker in several human cancers including head and neck cancer, perianal lesions, melanomas, gliomas, lymphomas, and some types of leukemia. p16 is also clinically indicated in carcinomas of the esophagus, pancreas, lung, biliary tract, liver, colon, and urinary bladder.
The p16 (p16<sup>INK4A</sup>) protein is a cyclin-dependent kinase (CDK) inhibitor that plays an important regulatory role in the cell cycle. By controlling the transition between the G1 and S phases through regulation of retinoblastoma protein, p16 decelerates cellular differentiation and therefore acts as a tumor suppressor, making it the key marker in several human cancers including head and neck cancer, perianal lesions, melanomas, gliomas, lymphomas, and some types of leukemia. p16 is also clinically indicated in carcinomas of the esophagus, pancreas, lung, biliary tract, liver, colon, and urinary bladder.
The p16 (p16<sup>INK4A</sup>) protein is a cyclin-dependent kinase (CDK) inhibitor that plays an important regulatory role in the cell cycle. By controlling the transition between the G1 and S phases through regulation of retinoblastoma protein, p16 decelerates cellular differentiation and therefore acts as a tumor suppressor, making it the key marker in several human cancers including head and neck cancer, perianal lesions, melanomas, gliomas, lymphomas, and some types of leukemia. p16 is also clinically indicated in carcinomas of the esophagus, pancreas, lung, biliary tract, liver, colon, and urinary bladder.
The p16 (p16<sup>INK4A</sup>) protein is a cyclin-dependent kinase (CDK) inhibitor that plays an important regulatory role in the cell cycle. By controlling the transition between the G1 and S phases through regulation of retinoblastoma protein, p16 decelerates cellular differentiation and therefore acts as a tumor suppressor, making it the key marker in several human cancers including head and neck cancer, perianal lesions, melanomas, gliomas, lymphomas, and some types of leukemia. p16 is also clinically indicated in carcinomas of the esophagus, pancreas, lung, biliary tract, liver, colon, and urinary bladder.
The p16 (p16<sup>INK4A</sup>) protein is a cyclin-dependent kinase (CDK) inhibitor that plays an important regulatory role in the cell cycle. By controlling the transition between the G1 and S phases through regulation of retinoblastoma protein, p16 decelerates cellular differentiation and therefore acts as a tumor suppressor, making it the key marker in several human cancers including head and neck cancer, perianal lesions, melanomas, gliomas, lymphomas, and some types of leukemia. p16 is also clinically indicated in carcinomas of the esophagus, pancreas, lung, biliary tract, liver, colon, and urinary bladder.
The p16 (p16<sup>INK4A</sup>) protein is a cyclin-dependent kinase (CDK) inhibitor that plays an important regulatory role in the cell cycle. By controlling the transition between the G1 and S phases through regulation of retinoblastoma protein, p16 decelerates cellular differentiation and therefore acts as a tumor suppressor, making it the key marker in several human cancers including head and neck cancer, perianal lesions, melanomas, gliomas, lymphomas, and some types of leukemia. p16 is also clinically indicated in carcinomas of the esophagus, pancreas, lung, biliary tract, liver, colon, and urinary bladder.
p120 Catenin is a nucleolar protein belonging to the armadillo protein family, which is involved in cell-cell adhesion and signal transduction. p120 Catenin is associated with proliferation, and is found in the majority of human malignant tumours, while remaining absent from resting normal cells. Anti-p120 Catenin is useful in differentiating between ductal and lobular neoplasia in the breast, and strong staining with Anti-p120 Catenin is associated with discohesive infiltrative morphology in gastric and colonic carcinoma. Accumulation of p120 Catenin in the cytoplasm has been linked to lung cancer, pancreatic cancer, and gastric cancer, and is correlated to poor prognosis in colon cancer.
Product Type:
Positive Control Slides
Storage Temp:
-20 degrees Celsius
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Application Details:
1:200
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
p120 Catenin is a nucleolar protein belonging to the armadillo protein family, which is involved in cell-cell adhesion and signal transduction. p120 Catenin is associated with proliferation, and is found in the majority of human malignant tumours, while remaining absent from resting normal cells. Anti-p120 Catenin is useful in differentiating between ductal and lobular neoplasia in the breast, and strong staining with Anti-p120 Catenin is associated with discohesive infiltrative morphology in gastric and colonic carcinoma. Accumulation of p120 Catenin in the cytoplasm has been linked to lung cancer, pancreatic cancer, and gastric cancer, and is correlated to poor prognosis in colon cancer.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC120
Antibody Isotype:
IgG1
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Lobular Breast Carcinoma
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
p120 Catenin is a nucleolar protein belonging to the armadillo protein family, which is involved in cell-cell adhesion and signal transduction. p120 Catenin is associated with proliferation, and is found in the majority of human malignant tumours, while remaining absent from resting normal cells. Anti-p120 Catenin is useful in differentiating between ductal and lobular neoplasia in the breast, and strong staining with Anti-p120 Catenin is associated with discohesive infiltrative morphology in gastric and colonic carcinoma. Accumulation of p120 Catenin in the cytoplasm has been linked to lung cancer, pancreatic cancer, and gastric cancer, and is correlated to poor prognosis in colon cancer.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC120
Antibody Isotype:
IgG1
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Lobular Breast Carcinoma
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
p120 Catenin is a nucleolar protein belonging to the armadillo protein family, which is involved in cell-cell adhesion and signal transduction. p120 Catenin is associated with proliferation, and is found in the majority of human malignant tumours, while remaining absent from resting normal cells. Anti-p120 Catenin is useful in differentiating between ductal and lobular neoplasia in the breast, and strong staining with Anti-p120 Catenin is associated with discohesive infiltrative morphology in gastric and colonic carcinoma. Accumulation of p120 Catenin in the cytoplasm has been linked to lung cancer, pancreatic cancer, and gastric cancer, and is correlated to poor prognosis in colon cancer.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Predilute
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC120
Antibody Isotype:
IgG1
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Lobular Breast Carcinoma
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
OX40 is a member of the tumor necrosis factor (TNF) receptor superfamily, which regulates T cell activity and immune response. OX40 is mainly activated by CD4 + and CD8 + T cells. It is expressed on cells, while OX40 ligands (OX40L, TNFSF4, CD252) are mainly expressed on activated antigen-presenting cells. Research shows that OX40 pathway is related to inflammation and autoimmune diseases. Other studies have shown that OX40 agonists can enhance the anti-tumor immunity of several cancer types.
OX40 is a member of the tumor necrosis factor (TNF) receptor superfamily, which regulates T cell activity and immune response. OX40 is mainly activated by CD4 + and CD8 + T cells. It is expressed on cells, while OX40 ligands (OX40L, TNFSF4, CD252) are mainly expressed on activated antigen-presenting cells. Research shows that OX40 pathway is related to inflammation and autoimmune diseases. Other studies have shown that OX40 agonists can enhance the anti-tumor immunity of several cancer types.
OX40 is a member of the tumor necrosis factor (TNF) receptor superfamily, which regulates T cell activity and immune response. OX40 is mainly activated by CD4 + and CD8 + T cells. It is expressed on cells, while OX40 ligands (OX40L, TNFSF4, CD252) are mainly expressed on activated antigen-presenting cells. Research shows that OX40 pathway is related to inflammation and autoimmune diseases. Other studies have shown that OX40 agonists can enhance the anti-tumor immunity of several cancer types.
OX40 is a member of the tumor necrosis factor (TNF) receptor superfamily, which regulates T cell activity and immune response. OX40 is mainly activated by CD4 + and CD8 + T cells. It is expressed on cells, while OX40 ligands (OX40L, TNFSF4, CD252) are mainly expressed on activated antigen-presenting cells. Research shows that OX40 pathway is related to inflammation and autoimmune diseases. Other studies have shown that OX40 agonists can enhance the anti-tumor immunity of several cancer types.
Octamer-Binding Transcription Factor 4 (Oct-4), also known as POU5F1 (POU Domain, Class 5, Transcription Factor 1), is a member of the POU homeodomain family of transcription factors and is involved in the maintenance and regulation of pluripotency in embryonic stem and germ cells. Anti-Oct-4 is highly useful and sensitive for seminomas, germinoma, dysgerminoma, embryonal carcinoma, and gonadoblastoma. Oct-4 may be associated with tumourigenesis, and can have an effect on some aspects of tumour behavior, including tumour recurrence or resistance to therapies.
Product Type:
Positive Control Slides
Storage Temp:
-20 degrees Celsius
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Application Details:
1:200
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Octamer-Binding Transcription Factor 4 (Oct-4), also known as POU5F1 (POU Domain, Class 5, Transcription Factor 1), is a member of the POU homeodomain family of transcription factors and is involved in the maintenance and regulation of pluripotency in embryonic stem and germ cells. Anti-Oct-4 is highly useful and sensitive for seminomas, germinoma, dysgerminoma, embryonal carcinoma, and gonadoblastoma. Oct-4 may be associated with tumourigenesis, and can have an effect on some aspects of tumour behavior, including tumour recurrence or resistance to therapies.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC643
Antibody Isotype:
IgG1
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Seminoma
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Octamer-Binding Transcription Factor 4 (Oct-4), also known as POU5F1 (POU Domain, Class 5, Transcription Factor 1), is a member of the POU homeodomain family of transcription factors and is involved in the maintenance and regulation of pluripotency in embryonic stem and germ cells. Anti-Oct-4 is highly useful and sensitive for seminomas, germinoma, dysgerminoma, embryonal carcinoma, and gonadoblastoma. Oct-4 may be associated with tumourigenesis, and can have an effect on some aspects of tumour behavior, including tumour recurrence or resistance to therapies.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC643
Antibody Isotype:
IgG1
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Seminoma
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Octamer-Binding Transcription Factor 4 (Oct-4), also known as POU5F1 (POU Domain, Class 5, Transcription Factor 1), is a member of the POU homeodomain family of transcription factors and is involved in the maintenance and regulation of pluripotency in embryonic stem and germ cells. Anti-Oct-4 is highly useful and sensitive for seminomas, germinoma, dysgerminoma, embryonal carcinoma, and gonadoblastoma. Oct-4 may be associated with tumourigenesis, and can have an effect on some aspects of tumour behavior, including tumour recurrence or resistance to therapies.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Predilute
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC643
Antibody Isotype:
IgG1
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Seminoma
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Neurotrophic tyrosine kinase receptor (NTRK) is a family of 3 proto-oncogenes including NTRK1, NTRK2, and NTRK3. NTRK gene fusions have been reported in a variety of tumor types, which are involved in biological processes such as neuronal survival, differentiation, and plasticity under physiological circumstances. Recently, FDA has approved ENtrectinib for patients with NTRK fusions, thus testing for NTRK fusions identifies patients who may be candidates for NTRK inhibitor therapy.
Neurotrophic tyrosine kinase receptor (NTRK) is a family of 3 proto-oncogenes including NTRK1, NTRK2, and NTRK3. NTRK gene fusions have been reported in a variety of tumor types, which are involved in biological processes such as neuronal survival, differentiation, and plasticity under physiological circumstances. Recently, FDA has approved ENtrectinib for patients with NTRK fusions, thus testing for NTRK fusions identifies patients who may be candidates for NTRK inhibitor therapy.
Neurotrophic tyrosine kinase receptor (NTRK) is a family of 3 proto-oncogenes including NTRK1, NTRK2, and NTRK3. NTRK gene fusions have been reported in a variety of tumor types, which are involved in biological processes such as neuronal survival, differentiation, and plasticity under physiological circumstances. Recently, FDA has approved ENtrectinib for patients with NTRK fusions, thus testing for NTRK fusions identifies patients who may be candidates for NTRK inhibitor therapy.
Neurotrophic tyrosine kinase receptor (NTRK) is a family of 3 proto-oncogenes including NTRK1, NTRK2, and NTRK3. NTRK gene fusions have been reported in a variety of tumor types, which are involved in biological processes such as neuronal survival, differentiation, and plasticity under physiological circumstances. Recently, FDA has approved ENtrectinib for patients with NTRK fusions, thus testing for NTRK fusions identifies patients who may be candidates for NTRK inhibitor therapy.
Neuron-Specific Enolase (NSE), also known as Enolase 2 (ENO2), is one of three enolase enzymes found in mammals, and acts as a phosphopyruvate hydratase. This mammalian glycolytic isoenzyme is located specifically in neurons of neuroendocrine cells, as well as tumours associated with those neurons. However, it has also been detected immunohistochemically in non-neoplastic cells of the pituitary, peptide-secreting tissues, pinealocytes, neuroendocrine cells of the lung, thyroid, parafollicular cells, adrenal medulla, islets of Langerhans, Merkel cells of the skin, and melanocytes. NSE is a useful marker for identifying normal striated muscle, hepatocytes, and peripheral nerves. Anti-NSE may detect for neuroendocrine differentiation, only when used in a panel of antibodies including more specific markers such as synaptophysin, chromogranin, and neurofilament.
Neuron-Specific Enolase (NSE), also known as Enolase 2 (ENO2), is one of three enolase enzymes found in mammals, and acts as a phosphopyruvate hydratase. This mammalian glycolytic isoenzyme is located specifically in neurons of neuroendocrine cells, as well as tumours associated with those neurons. However, it has also been detected immunohistochemically in non-neoplastic cells of the pituitary, peptide-secreting tissues, pinealocytes, neuroendocrine cells of the lung, thyroid, parafollicular cells, adrenal medulla, islets of Langerhans, Merkel cells of the skin, and melanocytes. NSE is a useful marker for identifying normal striated muscle, hepatocytes, and peripheral nerves. Anti-NSE may detect for neuroendocrine differentiation, only when used in a panel of antibodies including more specific markers such as synaptophysin, chromogranin, and neurofilament.
Neuron-Specific Enolase (NSE), also known as Enolase 2 (ENO2), is one of three enolase enzymes found in mammals, and acts as a phosphopyruvate hydratase. This mammalian glycolytic isoenzyme is located specifically in neurons of neuroendocrine cells, as well as tumours associated with those neurons. However, it has also been detected immunohistochemically in non-neoplastic cells of the pituitary, peptide-secreting tissues, pinealocytes, neuroendocrine cells of the lung, thyroid, parafollicular cells, adrenal medulla, islets of Langerhans, Merkel cells of the skin, and melanocytes. NSE is a useful marker for identifying normal striated muscle, hepatocytes, and peripheral nerves. Anti-NSE may detect for neuroendocrine differentiation, only when used in a panel of antibodies including more specific markers such as synaptophysin, chromogranin, and neurofilament.
Neuron-Specific Enolase (NSE), also known as Enolase 2 (ENO2), is one of three enolase enzymes found in mammals, and acts as a phosphopyruvate hydratase. This mammalian glycolytic isoenzyme is located specifically in neurons of neuroendocrine cells, as well as tumours associated with those neurons. However, it has also been detected immunohistochemically in non-neoplastic cells of the pituitary, peptide-secreting tissues, pinealocytes, neuroendocrine cells of the lung, thyroid, parafollicular cells, adrenal medulla, islets of Langerhans, Merkel cells of the skin, and melanocytes. NSE is a useful marker for identifying normal striated muscle, hepatocytes, and peripheral nerves. Anti-NSE may detect for neuroendocrine differentiation, only when used in a panel of antibodies including more specific markers such as synaptophysin, chromogranin, and neurofilament.
Neurofilaments are a group of intermediate filaments found abundantly around the axons of vertebrate neurons. They are also expressed in paragangliomas, adrenal pheochromocytomas, Merkel cell tumours, carcinoid tumours, neuroendocrine carcinomas of the skin, and oat cell carcinomas of the lung. Anti-Neurofilament stains a variety of neural, neuroendocrine, and endocrine tumours, such as neuromas, ganglioneuromas, gangliogliomas, ganglioneuroblastomas, and neuroblastomas.
Product Type:
Positive Control Slides
Storage Temp:
-20 degrees Celsius
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Application Details:
1:200
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Neurofilaments are a group of intermediate filaments found abundantly around the axons of vertebrate neurons. They are also expressed in paragangliomas, adrenal pheochromocytomas, Merkel cell tumours, carcinoid tumours, neuroendocrine carcinomas of the skin, and oat cell carcinomas of the lung. Anti-Neurofilament stains a variety of neural, neuroendocrine, and endocrine tumours, such as neuromas, ganglioneuromas, gangliogliomas, ganglioneuroblastomas, and neuroblastomas.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC639
Antibody Isotype:
IgG1
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Brain
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Neurofilaments are a group of intermediate filaments found abundantly around the axons of vertebrate neurons. They are also expressed in paragangliomas, adrenal pheochromocytomas, Merkel cell tumours, carcinoid tumours, neuroendocrine carcinomas of the skin, and oat cell carcinomas of the lung. Anti-Neurofilament stains a variety of neural, neuroendocrine, and endocrine tumours, such as neuromas, ganglioneuromas, gangliogliomas, ganglioneuroblastomas, and neuroblastomas.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC639
Antibody Isotype:
IgG1
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Brain
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Neurofilaments are a group of intermediate filaments found abundantly around the axons of vertebrate neurons. They are also expressed in paragangliomas, adrenal pheochromocytomas, Merkel cell tumours, carcinoid tumours, neuroendocrine carcinomas of the skin, and oat cell carcinomas of the lung. Anti-Neurofilament stains a variety of neural, neuroendocrine, and endocrine tumours, such as neuromas, ganglioneuromas, gangliogliomas, ganglioneuroblastomas, and neuroblastomas.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Predilute
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC639
Antibody Isotype:
IgG1
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Brain
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Nerve Growth Factor Receptor (NGFR), also known as p75, P-75NTR, or CD271, is a neurotrophin receptor belonging to the tumour necrosis factor receptor family. It is expressed mainly in Schwann cells and neurons, as well as a number of other non-neuronal cell types, and is also expressed in melanocytes, melanomas, neuroblastomas, pheochromocytomas, neurofibromas, neurotized nevi (type C melanocytes), and other neural crest cell or tumour derivatives. It has been suggested that NGFR may act as a tumour suppressor indicated in prostate and urothelial cancer, and Anti-NGFR is often used in adjunct with S100, to aid in the diagnosis of desmoplastic and neurotrophic malignant melanomas. Anti-NGFR is also useful as an aid in the diagnosis of breast malignancy, as the antibody labels the myoepithelial cells of breast ducts and intralobular fibroblasts of breast ducts.
Product Type:
Positive Control Slides
Storage Temp:
-20 degrees Celsius
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Application Details:
1:200
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Nerve Growth Factor Receptor (NGFR), also known as p75, P-75NTR, or CD271, is a neurotrophin receptor belonging to the tumour necrosis factor receptor family. It is expressed mainly in Schwann cells and neurons, as well as a number of other non-neuronal cell types, and is also expressed in melanocytes, melanomas, neuroblastomas, pheochromocytomas, neurofibromas, neurotized nevi (type C melanocytes), and other neural crest cell or tumour derivatives. It has been suggested that NGFR may act as a tumour suppressor indicated in prostate and urothelial cancer, and Anti-NGFR is often used in adjunct with S100, to aid in the diagnosis of desmoplastic and neurotrophic malignant melanomas. Anti-NGFR is also useful as an aid in the diagnosis of breast malignancy, as the antibody labels the myoepithelial cells of breast ducts and intralobular fibroblasts of breast ducts.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC637
Antibody Isotype:
IgG1, kappa
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Breast
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Nerve Growth Factor Receptor (NGFR), also known as p75, P-75NTR, or CD271, is a neurotrophin receptor belonging to the tumour necrosis factor receptor family. It is expressed mainly in Schwann cells and neurons, as well as a number of other non-neuronal cell types, and is also expressed in melanocytes, melanomas, neuroblastomas, pheochromocytomas, neurofibromas, neurotized nevi (type C melanocytes), and other neural crest cell or tumour derivatives. It has been suggested that NGFR may act as a tumour suppressor indicated in prostate and urothelial cancer, and Anti-NGFR is often used in adjunct with S100, to aid in the diagnosis of desmoplastic and neurotrophic malignant melanomas. Anti-NGFR is also useful as an aid in the diagnosis of breast malignancy, as the antibody labels the myoepithelial cells of breast ducts and intralobular fibroblasts of breast ducts.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC637
Antibody Isotype:
IgG1, kappa
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Breast
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Nerve Growth Factor Receptor (NGFR), also known as p75, P-75NTR, or CD271, is a neurotrophin receptor belonging to the tumour necrosis factor receptor family. It is expressed mainly in Schwann cells and neurons, as well as a number of other non-neuronal cell types, and is also expressed in melanocytes, melanomas, neuroblastomas, pheochromocytomas, neurofibromas, neurotized nevi (type C melanocytes), and other neural crest cell or tumour derivatives. It has been suggested that NGFR may act as a tumour suppressor indicated in prostate and urothelial cancer, and Anti-NGFR is often used in adjunct with S100, to aid in the diagnosis of desmoplastic and neurotrophic malignant melanomas. Anti-NGFR is also useful as an aid in the diagnosis of breast malignancy, as the antibody labels the myoepithelial cells of breast ducts and intralobular fibroblasts of breast ducts.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Predilute
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC637
Antibody Isotype:
IgG1, kappa
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Breast
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Napsin A is a pepsin-like aspartic proteinase that is closely related to Napsin B. It is expressed mainly in the lung and kidney, and is involved in the correct folding, targeting, and control of aspartic proteinase zymogens. Napsin A expression has been indicated in type II pneumocytes and adenocarcinomas of the lung and kidney. Anti-Napsin A is also useful for differentiating between primary lung adenocarcinomas and adenocarcinomas of other organs, due to the high expression of Napsin A in adenocarcinomas of the lung.
Napsin A is a pepsin-like aspartic proteinase that is closely related to Napsin B. It is expressed mainly in the lung and kidney, and is involved in the correct folding, targeting, and control of aspartic proteinase zymogens. Napsin A expression has been indicated in type II pneumocytes and adenocarcinomas of the lung and kidney. Anti-Napsin A is also useful for differentiating between primary lung adenocarcinomas and adenocarcinomas of other organs, due to the high expression of Napsin A in adenocarcinomas of the lung.
Napsin A is a pepsin-like aspartic proteinase that is closely related to Napsin B. It is expressed mainly in the lung and kidney, and is involved in the correct folding, targeting, and control of aspartic proteinase zymogens. Napsin A expression has been indicated in type II pneumocytes and adenocarcinomas of the lung and kidney. Anti-Napsin A is also useful for differentiating between primary lung adenocarcinomas and adenocarcinomas of other organs, due to the high expression of Napsin A in adenocarcinomas of the lung.
Ki-67 is a nuclear, non-histone protein that is expressed only during active phases of the cell cycle (G1, S, G2 and M), but not in the resting phases (G0 and G1 early phase). Although the antigen has also been associated with ribosomal RNA transcription, it is strongly linked to cell proliferation and has thus been indicated as an effective marker in grading the proliferation rate of tumours, including those of the brain, breast, cervix, and prostate.
KBA.62, also known as Melanoma Associated Antigen, is used to detect an antigen present in melanocytic tumours, such as melanomas, due to its proven sensitivity and specificity. The antibody can also be used to distinguish between junctional nevus and intradermal nevus cells, and fetal melanocytes versus normal adult melanocytes. Studies have shown KBA.62 to be highly useful in differentiating between metastatic amelanotic melanoma and a number of poorly differentiated carcinomas, large cell lymphomas, sarcomas, and spindle cell carcinomas.
Product Type:
Positive Control Slides
Storage Temp:
-20 degrees Celsius
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Application Details:
1:200
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
KBA.62, also known as Melanoma Associated Antigen, is used to detect an antigen present in melanocytic tumours, such as melanomas, due to its proven sensitivity and specificity. The antibody can also be used to distinguish between junctional nevus and intradermal nevus cells, and fetal melanocytes versus normal adult melanocytes. Studies have shown KBA.62 to be highly useful in differentiating between metastatic amelanotic melanoma and a number of poorly differentiated carcinomas, large cell lymphomas, sarcomas, and spindle cell carcinomas.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC062
Antibody Isotype:
IgG1
Application Details:
1:200
Regulatory Status:
RUO
Positive Control:
Melanoma
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
KBA.62, also known as Melanoma Associated Antigen, is used to detect an antigen present in melanocytic tumours, such as melanomas, due to its proven sensitivity and specificity. The antibody can also be used to distinguish between junctional nevus and intradermal nevus cells, and fetal melanocytes versus normal adult melanocytes. Studies have shown KBA.62 to be highly useful in differentiating between metastatic amelanotic melanoma and a number of poorly differentiated carcinomas, large cell lymphomas, sarcomas, and spindle cell carcinomas.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC062
Antibody Isotype:
IgG1
Application Details:
1:200
Regulatory Status:
RUO
Positive Control:
Melanoma
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
KBA.62, also known as Melanoma Associated Antigen, is used to detect an antigen present in melanocytic tumours, such as melanomas, due to its proven sensitivity and specificity. The antibody can also be used to distinguish between junctional nevus and intradermal nevus cells, and fetal melanocytes versus normal adult melanocytes. Studies have shown KBA.62 to be highly useful in differentiating between metastatic amelanotic melanoma and a number of poorly differentiated carcinomas, large cell lymphomas, sarcomas, and spindle cell carcinomas.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Predilute
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC062
Antibody Isotype:
IgG1
Application Details:
1:200
Regulatory Status:
RUO
Positive Control:
Melanoma
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Anti-Kappa recognizes surface immunoglobulin on normal and neoplastic B-cells, and has been indicated as a potential aid in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas, where the expression of a single light chain class is restricted. The determination of light chain ratio is critical in evaluating B-cell neoplasms, as the majority of B-cell lymphomas express either kappa or lambda light chains, while a mixture of kappa and lambda is characteristic of reactive proliferations. In paraffin-embedded tissue, Anti-Kappa displays strong staining of kappa-positive plasma cells, as well as cells that have absorbed exogenous immunoglobulins.
Anti-Kappa recognizes surface immunoglobulin on normal and neoplastic B-cells, and has been indicated as a potential aid in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas, where the expression of a single light chain class is restricted. The determination of light chain ratio is critical in evaluating B-cell neoplasms, as the majority of B-cell lymphomas express either kappa or lambda light chains, while a mixture of kappa and lambda is characteristic of reactive proliferations. In paraffin-embedded tissue, Anti-Kappa displays strong staining of kappa-positive plasma cells, as well as cells that have absorbed exogenous immunoglobulins.
Anti-Kappa recognizes surface immunoglobulin on normal and neoplastic B-cells, and has been indicated as a potential aid in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas, where the expression of a single light chain class is restricted. The determination of light chain ratio is critical in evaluating B-cell neoplasms, as the majority of B-cell lymphomas express either kappa or lambda light chains, while a mixture of kappa and lambda is characteristic of reactive proliferations. In paraffin-embedded tissue, Anti-Kappa displays strong staining of kappa-positive plasma cells, as well as cells that have absorbed exogenous immunoglobulins.
Anti-Kappa recognizes surface immunoglobulin on normal and neoplastic B-cells, and has been indicated as a potential aid in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas, where the expression of a single light chain class is restricted. The determination of light chain ratio is critical in evaluating B-cell neoplasms, as the majority of B-cell lymphomas express either kappa or lambda light chains, while a mixture of kappa and lambda is characteristic of reactive proliferations. In paraffin-embedded tissue, Anti-Kappa displays strong staining of kappa-positive plasma cells, as well as cells that have absorbed exogenous immunoglobulins.
Anti-Kappa recognizes surface immunoglobulin on normal and neoplastic B-cells, and has been indicated as a potential aid in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas, where the expression of a single light chain class is restricted. The determination of light chain ratio is critical in evaluating B-cell neoplasms, as the majority of B-cell lymphomas express either kappa or lambda light chains, while a mixture of kappa and lambda is characteristic of reactive proliferations. In paraffin-embedded tissue, Anti-Kappa displays strong staining of kappa-positive plasma cells, as well as cells that have absorbed exogenous immunoglobulins.
Product Type:
Positive Control Slides
Storage Temp:
-20 degrees Celsius
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Application Details:
1:200
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Anti-Kappa recognizes surface immunoglobulin on normal and neoplastic B-cells, and has been indicated as a potential aid in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas, where the expression of a single light chain class is restricted. The determination of light chain ratio is critical in evaluating B-cell neoplasms, as the majority of B-cell lymphomas express either kappa or lambda light chains, while a mixture of kappa and lambda is characteristic of reactive proliferations. In paraffin-embedded tissue, Anti-Kappa displays strong staining of kappa-positive plasma cells, as well as cells that have absorbed exogenous immunoglobulins.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC609
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Pancreas
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Anti-Kappa recognizes surface immunoglobulin on normal and neoplastic B-cells, and has been indicated as a potential aid in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas, where the expression of a single light chain class is restricted. The determination of light chain ratio is critical in evaluating B-cell neoplasms, as the majority of B-cell lymphomas express either kappa or lambda light chains, while a mixture of kappa and lambda is characteristic of reactive proliferations. In paraffin-embedded tissue, Anti-Kappa displays strong staining of kappa-positive plasma cells, as well as cells that have absorbed exogenous immunoglobulins.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC609
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Pancreas
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Anti-Kappa recognizes surface immunoglobulin on normal and neoplastic B-cells, and has been indicated as a potential aid in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas, where the expression of a single light chain class is restricted. The determination of light chain ratio is critical in evaluating B-cell neoplasms, as the majority of B-cell lymphomas express either kappa or lambda light chains, while a mixture of kappa and lambda is characteristic of reactive proliferations. In paraffin-embedded tissue, Anti-Kappa displays strong staining of kappa-positive plasma cells, as well as cells that have absorbed exogenous immunoglobulins.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Predilute
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC609
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Pancreas
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Indoleamine 2,3-dioxygenase 1 (IDO1) is a cytoplasmic enzyme encoded by the INDO gene on human chromosome 8p22. IDO1 modulates levels of the amino acid tryptophan, which is vital for cell growth, but is also involved in immune evasion and tumor outgrowth. Blocking the IDO1 pathway may be a potential target for immuno and cancer therapy. IDO1 expressions have been found in endometrial, cervical carcinomas, renal cell carcinomas, non-small cell lung carcinomas, and colorectal carcinomas.
Product Type:
Positive Control Slides
Storage Temp:
-20 degrees Celsius
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Application Details:
1:200
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Indoleamine 2,3-dioxygenase 1 (IDO1) is a cytoplasmic enzyme encoded by the INDO gene on human chromosome 8p22. IDO1 modulates levels of the amino acid tryptophan, which is vital for cell growth, but is also involved in immune evasion and tumor outgrowth. Blocking the IDO1 pathway may be a potential target for immuno and cancer therapy. IDO1 expressions have been found in endometrial, cervical carcinomas, renal cell carcinomas, non-small cell lung carcinomas, and colorectal carcinomas.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC701
Antibody Isotype:
IgG2a, kappa
Application Details:
1:200
Regulatory Status:
RUO
Positive Control:
Tonsil
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Indoleamine 2,3-dioxygenase 1 (IDO1) is a cytoplasmic enzyme encoded by the INDO gene on human chromosome 8p22. IDO1 modulates levels of the amino acid tryptophan, which is vital for cell growth, but is also involved in immune evasion and tumor outgrowth. Blocking the IDO1 pathway may be a potential target for immuno and cancer therapy. IDO1 expressions have been found in endometrial, cervical carcinomas, renal cell carcinomas, non-small cell lung carcinomas, and colorectal carcinomas.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC701
Antibody Isotype:
IgG2a, kappa
Application Details:
1:200
Regulatory Status:
RUO
Positive Control:
Tonsil
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Indoleamine 2,3-dioxygenase 1 (IDO1) is a cytoplasmic enzyme encoded by the INDO gene on human chromosome 8p22. IDO1 modulates levels of the amino acid tryptophan, which is vital for cell growth, but is also involved in immune evasion and tumor outgrowth. Blocking the IDO1 pathway may be a potential target for immuno and cancer therapy. IDO1 expressions have been found in endometrial, cervical carcinomas, renal cell carcinomas, non-small cell lung carcinomas, and colorectal carcinomas.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Predilute
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC701
Antibody Isotype:
IgG2a, kappa
Application Details:
1:200
Regulatory Status:
RUO
Positive Control:
Tonsil
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Isocitrate Dehydrogenase 1 (IDH1) is a soluble, cytoclic enzyme involved in the TCA metablic cycle. The most notable mutation in this enzyme, R132H, is clinically indicated in the majority of astrocytomas and oligodendroglial tumours, with the mutation being associated with more favourable prognosis and increased survival in those patients. IDH1 R132H is also useful in the differential diagnosis between anaplastic glioma and glioblastoma.
Isocitrate Dehydrogenase 1 (IDH1) is a soluble, cytoclic enzyme involved in the TCA metablic cycle. The most notable mutation in this enzyme, R132H, is clinically indicated in the majority of astrocytomas and oligodendroglial tumours, with the mutation being associated with more favourable prognosis and increased survival in those patients. IDH1 R132H is also useful in the differential diagnosis between anaplastic glioma and glioblastoma.
Isocitrate Dehydrogenase 1 (IDH1) is a soluble, cytoclic enzyme involved in the TCA metablic cycle. The most notable mutation in this enzyme, R132H, is clinically indicated in the majority of astrocytomas and oligodendroglial tumours, with the mutation being associated with more favourable prognosis and increased survival in those patients. IDH1 R132H is also useful in the differential diagnosis between anaplastic glioma and glioblastoma.
